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ABSTRACT 
Advanced cell therapies are evolving at an enormous pace. Mesenchymal 
stromal cells (MSCs) have become the focus of cell based therapies due to their 
capacity to home to the site of infection or tissue damage, to suppress immune 
reactions, and to support the regeneration of tissues. Bone marrow (BM) is a 
rich source of MSCs but other sources, such as cord blood (CB), have been 
presented as an attractive alternative because of the ease of access and 
abundance of this material. A good culture method constitutes the basis for 
clinical production of MSCs. The traditional cell culture method of BM-derived 
MSCs (BM-MSCs) is not an efficient technique for obtaining MSCs from CB. 
Thus, the development of cell culture methods is necessary for this material to 
be utilized in MSC research and therapy. Even small changes in the environment 
of MSCs may alter the phenotype or functional capacity of these cells. The 
knowledge of the functional capacities of MSCs and conditions that impact them 
will help in production of specific MSCs for various indications. 
The aim of this thesis was to establish a culture condition for efficient 
production of MSCs from human CB and to compare different good 
manufacturing practice (GMP)-compliant methods to establish a robust method 
to culture human BM-MSCs in platelet lysate (PL)-containing culture medium. 
The impact of culture conditions, both culture media and oxygen (O2) 
concentration, on the characteristics and functionality of MSCs was studied. 
Another aim of this thesis was to gain knowledge about the immunosuppressive 
mechanisms of MSCs.  
The culture method to obtain MSCs from human CB established in this thesis 
was efficient in obtaining MSCs from almost 90% of processed CB-units. This 
figure is much higher than presented previously in literature. As a result of the 
comparison of two different GMP-compliant culture methods for obtaining 
adequate numbers of BM-MSCs, we identified a robust method to culture MSCs 
for clinical purposes. The results from culturing MSCs in different O2 
concentrations indicated that low O2 concentrations are beneficial for the MSC 
proliferation at late passages but this supportive impact is minimal at early 
passages. Culturing the cells in different media was demonstrated to impact the 
phenotype and functional capacities of MSCs. The expression of cell surface 
markers CD90 and HLA-DR was altered by different culture media. The 
functional capacities of MSCs were also influenced by different culture media. 
CB-MSCs cultured in medium without dexamethasone (DX) and containing only 
small amounts of growth factors showed a higher capacity to support 
angiogenesis than MSCs cultured in the presence of DX and in growth factor-
rich medium. On the other hand, MSCs cultured in the presence of DX and 
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growth factor-rich medium were more efficient in suppressing T cell 
proliferation. 
In this thesis, a novel mechanism for human MSCs and MSC-derived 
extracellular vesicles (MSC-EVs) to suppress T cell proliferation via adenosine 
(Ado) production was demonstrated. Ado was efficiently produced from ATP by 
the action of CD73 molecule on MSCs in concert with CD39 expressing T cells.  
In conclusion, this thesis presents an efficient method for obtaining MSCs 
from CB and a GMP-compliant method for culturing BM-MSCs for clinical use. 
The culture medium and O2 concentration have an effect on the proliferative 
potential, surface characteristics and functionality of MSCs, and they should be 
carefully studied when altering the culture protocols. This thesis also presents a 
novel immunomodulatory mechanism of MSCs, mediated by the activity of cell 
surface molecule CD73. 
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ABBREVIATIONS 
Ado  Adenosine 
ADP  Adenosine diphosphate 
AMP  Adenosine monophosphate 
AT   Adipose tissue 
AT-MSCs  Adipose tissue-derived mesenchymal stromal cells 
ATMP  Advanced therapy medicinal products 
ATP   Adenosine triphosphate 
bFGF   Basic fibroblast growth factor  
BM  Bone marrow 
BM-MSCs  Bone marrow-derived mesenchymal stromal cells 
CAT  Committee for Advanced Therapies, at EMA 
CB  Cord blood 
CB-MSCs  Cord blood-derived mesenchymal stromal cells 
CD  Cluster of differentiation 
CFU-F   Colony-forming unit –fibroblasts 
CM  Conditioned medium 
CO2  Carbon dioxide  
DC  Dendritic cell 
DX  Dexamethasone 
EGF  Epidermal growth factor  
EHNA  erythro-9-(2-hydroxy-3-nonyl)adenine, adenosine 
  deaminase inhibitor 
ELISA  Enzyme-linked immunosorbent assay 
EMA  European Medicines Agency 
ESC  Embryonic stem cell 
EV  Extracellular vesicle 
FBS  Fetal bovine serum 
FN  Fibronectin 
GMP  Good manufacturing practice 
GVHD  Graft versus host disease 
HLA  Human leucocyte antigen 
HOX  Homeobox 
HPLC  High-performance liquid chromatography 
HSC  Hematopoietic stem cell 
IDO  Idoleamine-2,3-oxygenase 
IFNγ  Interferon gamma 
IL  Interleukin 
iPS cell  Induced pluripotent stem cell 
ISCT  International Society for Cellular Therapy  
M1  Medium 1 
M2  Medium 2 
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M3  Medium 3 
MAPC  Multi potent adult progenitor cell 
MC  Mononuclear cell 
MIAMI cells Marrow-isolated adult multi-lineage inducible cells 
MSC  Mesenchymal stromal/stem cell 
MSC-EV  Mesenchymal stromal cell-derived extracellular  
  vesicles  
MV  Microvesicle 
NK cell  Natural killer cell 
O2  Oxygen 
PBMC  Peripheral blood mononuclear cell 
PD  Population doubling 
PDGF-BB  Platelet derived growth factor-BB 
PL  Platelet lysate 
PRP  Platelet rich plasma 
qRT-PCR  Quantitative real-time polymerase chain reaction 
RT-PCR  Reverse transcription polymerase chain reaction 
sCTMP  Somatic cell therapy medicinal product 
StdM  Standard growth medium 
TEP  Tissue-engineered product 
TGF  Transforming growth factor 
TLR  Toll like receptor 
Treg  Regulatory T cell 
UC  Umbilical cord 
UC-MSCs  Umbilical cord-derived MSCs 
USSC  Unrestricted somatic stem cells 
VEGF  Vascular endothelial growth factor 
  
 
 
Review of the literature 
12 
1 REVIEW OF THE LITERATURE 
1.1 CELL THERAPIES 
Cell therapy is defined as the administration of live cells into a patient with 
the intention to replace, augment, or modify the function of patients’ cells 
that are diseased, dysfunctional, or missing. Cell therapy is another 
therapeutic application to complement the traditional pharmaceuticals, 
biopharmaceuticals, and medical devices in treatment of patients (Mason et 
al. 2011). Cell therapies can be conducted using either autologous or allogenic 
cell products. In autologous cell therapy, the patient is treated with his or her 
own cells in contrast to allogenic cell therapy which requires the 
transplantation of cells from a donor to a patient (Buckler et al. 2016). 
The field of cell therapies has grown enormously during last decades and 
it is still steadily expanding (see Figure 1). The worldwide stem cell therapy 
market is estimated to grow at a rate of 39.5% from 2015 to 2020 (Buckler et 
al. 2016). Once limited to blood and bone marrow (BM) transplantation and 
reproductive in vitro fertilization, the field of cell therapies has moved 
towards advanced cell therapies. Cell therapies cover a broad range of 
specialties and applications, divided in permanent and transient cell therapy 
categories. The permanent cell therapies include the replacement of damaged 
tissue with functional cells such as damaged cornea replaced with corneal 
epithelial stem cells. The transient cell therapies include therapies such as 
the immunomodulatory therapy provided by adult stem cells (Mason et al. 
2011). 
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 Number of cell therapy trials. (A) The total number of cell therapy trials from 2011 to Figure 1
 2015. The total number of cell therapy trials was 631 in 2015 according to Alliance 
 for Regenerative Medicine. (B) The number of cell therapy trials by cell type from 
 2011 to 2014 modified from Bersenev 2015. Data from  Bersenev 2015 (Bersenev 
 2015) and from Annual Data Report by Alliance for Regenerative Medicine 
 (http://alliancerm.org/sites/default/files/ARM_Annual_Report_2015_Web_Version_F
 INAL.pd). Abbreviations: MSC, mesenchymal stromal cells; BM-MC, bone marrow 
 mononuclear cells; HSPC, hematopoietic stem/progenitor cells; ESC, embryonic 
 stem cells; DC, dendritic cells; NK, natural killer cells. 
 CELL TYPES IN CELL THERAPIES 1.1.1
Embryonic stem cells 
Embryonic stem cells (ESCs) are derived from the inner cell mass of the 
blastocyst stage of an embryo (Evans and Kaufman 1981; Thomson et al. 
1998). These rapidly proliferating pluripotent cells can be propagated in vitro 
indefinitely in particular culture conditions. The characteristics of cultured 
ESCs include the expression of some pluripotent markers (NANOG, SOX2, 
OCT4, and KLF4) and the cells have active telomerase and alkaline 
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phosphatase enzymes. Undifferentiated ESCs form teratomas (tumors with 
differentiated structures of ectoderm, mesoderm, and endoderm origin) 
when injected into an immune-deficient mouse, indicating their capacity to 
differentiate towards all three embryonic germ layers. ESCs can also be 
induced to differentiate into a range of committed somatic cells. Finding 
appropriate culture conditions to achieve efficient cell differentiation is one 
of the active areas within the ESC field (Alvarez et al. 2012). 
Although ESCs have properties that sound promising for regenerative 
medicine and tissue replacement after an injury or a disease, these cells have 
several disadvantages in cell therapies. These problems include ethical 
issues, teratoma formation, and immune reactions after transplantation 
(Jung 2009). However, some clinical trials have been conducted, the first 
being a treatment of patients with acute spinal cord injury by Geron 
corporation.  Geron Corporation started a phase I trial in 2010, using ESC-
derived oligodendrocytes and treated 4 of the 10 planned patients before 
stopping the trial for economic reasons (Scott and Magnus 2014). In 
addition, some other phase I trials with ESC-derived cells are ongoing for 
treating macular degeneration (Mead et al. 2015). 
Induced pluripotent stem cells 
In 2006, Takahashi and Yamanaka (Takahashi and Yamanaka 2006) 
described the creation of induced pluripotent stem (iPS) cells. These cells 
share similar characteristics with ESCs including self-renewal capacity and 
the capacity to differentiate into various cell types. These cells were initially 
generated from adult somatic cells by retroviral delivery of four transcription 
factors: Oct4, Sox2, Klf4, and cMyc (Takahashi and Yamanaka 2006). Since 
then, it has been demonstrated that most of these four factors can be 
substituted with different factors, though some key factors such as OCT4 
cannot be omitted (Yamanaka and Blau 2010).  
The use of virus vectors to create iPS cells may produce insertional 
mutations, thus resulting even in tumor genesis (Hyun et al. 2007). To 
overcome this, Yu et al. presented a vector and transgene free system to 
induce iPS (Yu et al. 2009). However, despite the recent progress in 
designing protocols that reduce the risk of viral integrations and oncogene 
expression in generation of iPS cells, there are still technical challenges in the 
production of these cells and safety concerns regarding their use in clinical 
applications which require solving before clinical use (Ji et al. 2016). 
While iPS cells possess similar pluripotent potential as ESCs, they do not 
have the same ethical problems as ESCs as they are derived from adult cells. 
They hold great potential for regenerative medicine as patient specific iPS 
cells can be generated to overcome the immune rejection typical of ESCs. iPS 
cells can also be used to model human diseases and screen drug candidates 
in vitro. In 2013, a clinical trial for macular degeneration with autologous iPS 
was started by Japanese RIKEN Center for Developmental Biology. The trial 
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was halted one year later due to mutations in second product and regulatory 
changes. The company also changed their strategy, deciding to move forward 
with allogenic iPS cells (http://stemcellassays.com/2015/09/first-ips-cell-
clinical-trial-insights/). 
Adult stem / progenitor cells 
Adult stem and progenitor cells, including tissue specific stem cells, are 
multipotent cells found in differentiated tissues. These cells have a self-
renewal capacity and the capacity to differentiate into the specialized cell 
types of the tissue. In contrast to ESCs, the differentiation capacity of adult 
stem cells is often restricted to certain lineages. Progenitor cells are described 
to have a more limited differentiation and self-renewal capacity than adult 
stem cells. The primary role of adult stem and progenitor cells is to maintain 
and repair the tissue where they reside. 
The best known adult stem cell type is the hematopoietic stem cells 
(HSCs), which reside in the BM and form all types of blood cells. HSCs are 
routinely used for therapeutic purposes as BM transplantations have been 
conducted for several decades (Storb 2003). Another adult stem cell or 
progenitor cell type, initially found in BM (Friedenstein et al. 1968), is 
mesenchymal stromal/stem cells (MSCs). They are multipotent adult cells 
found in virtually all tissues of the body (Crisan et al. 2008).  These 
multipotent cells have been called by several names due to their unique 
characteristics noticed in vitro. Besides MSCs, these multipotent cells 
include unrestricted somatic stem cells (USSC), marrow-isolated adult multi-
lineage inducible (MIAMI) cells, multi potent adult progenitor cells 
(MAPCs), and very small embryonic-like (VSEL) cells (D'Ippolito et al. 2004; 
Jiang et al. 2002; Kogler et al. 2004; Kucia et al. 2006). These cells have 
been demonstrated to have several unique features but it is still not clear if 
they are hierarchically related to each other and constitute overlapping 
populations of early-development stem cells or whether they are just a 
consequence of differential culture procedures (Suszynska et al. 2014).   
Several adult cell based products are already on the market. Holoclar® 
(Holostem Advanced Therapies), a stem cell therapy product, was the first 
advanced therapy medicinal product (ATMP) containing adult stem cells 
approved in the European Union (EU). This product consists of patient 
derived limbal stem cells and is used for the treatment of limbal stem cell 
deficiency due to physical or chemical burns of eyes 
(http://www.eurostemcell.org/story/europe-approves-holoclar-first-stem-
cell-based-medicinal-product). Another tissue specific product with market 
approval in Europe is ChondroCelect® (TiGenix), which contains autologous 
in vitro expanded chondrocytes for repair of cartilage defects of the knee 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000878/WC500026031.pdf.). 
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Immune cells 
Several immune cell types have potential for use in cell therapies.  Widely 
studied cell types in this field include T cells, natural killer (NK) cells, and 
dendritic cells, with the main focus on malignant and infectious disease 
therapies. 
In T cell therapies, T cells are cultured and/or engineered ex vivo and 
adoptively transferred into a patient, or T cells can be directly targeted by 
vaccination or biological compounds (Guo et al. 2015). T cell therapies 
include the use of pathogen specific T cells, tumor infiltrating leucocytes 
(TIL) (Rosenberg et al. 1988), cytotoxic T lymphocytes (CTL) against virus 
associated malignancies (Schuessler et al. 2014), and genetically engineered 
T cells such as chimeric antigen receptor (CAR) T cells (Gill et al. 2016). 
Pathogen-specific T cells include virus-specific T cells against viruses such as 
cytomegalovirus (CMV) (Einsele et al. 2002) and fungus-specific T cells (Deo 
and Gottlieb 2015). Donor lymphocyte infusion (DLI) is used to tackle a 
hematopoietic malignancy relapse after HSC transplantation (Chang and 
Huang 2013). Regulatory T cells (Treg) have also been used in clinic to 
reduce the incidence of graft versus host disease (GVHD) (Trzonkowski et al. 
2009). 
Besides T cells, also other immune cells have been found to be applicable 
in cell therapies. Early clinical and preclinical studies have indicated that NK 
cells have great potential for targeting tumor cells. Autologous and allogenic 
NK cells have been demonstrated to be safe and without toxic effects in 
several clinical studies aimed at targeting tumors. The major risk involved in 
the use of allogenic NK cells is the development of GVHD. Although NK cell 
therapies represent a promising therapy against cancer, clinical trials have 
not clearly demonstrated their benefits in patients with malignancies 
(Dahlberg et al. 2015). 
Dendritic cells (DCs) have also been used as immunotherapeutic agents 
against tumors. DC vaccines have been used in several clinical trials in cancer 
patients and sipuleucel-T (Provenge®, Dendreon Corporation), a product 
approved by authorities has shown significant survival advantage in 
metastatic castration-resistant prostate cancer (Mantia-Smaldone and Chu 
2013).    
1.2 MESENCHYMAL STROMAL CELLS 
Mesenchymal stromal cells (MSCs) have been studied since 1960s, pioneered 
by Friedenstein (Friedenstein et al. 1968). He managed to culture a plastic 
adherent fibroblastic cell type from BM, which he named colony-forming 
unit -fibroblasts (CFU-F) (Friedenstein et al. 1976). Since then, these cells 
have been studied worldwide, with several names given to them (Charbord 
2010; Horwitz et al. 2005). In 1991, these cells were named mesenchymal 
stem cells (Caplan 1991). Later on, International Society for Cellular Therapy 
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(ISCT) recommended that they be named multipotent mesenchymal stromal 
cells, using the same acronym MSC (Horwitz et al. 2005). This name was 
recommended as these cells do not literally fulfill the criteria for a true stem 
cell. MSCs have not been demonstrated to be capable of producing a tissue in 
vivo. A true stem cell should have self-renewal capacity, the capacity to 
produce differentiated progeny, and, when transplanted, they should be 
capable of regenerating a tissue.  
Since the initial finding of MSCs from BM, these cells have been derived 
from various sources (Erices et al. 2000; Gronthos et al. 2000; in 't Anker et 
al. 2004; Wang et al. 2004; Zuk et al. 2002). They can be found in nearly all 
adult tissues where they are mostly located in the perivascular areas (Crisan 
et al. 2008). Actually, these cells share similarities with pericytes and thus 
there is a theory that the in vivo niche of MSCs is the perivascular area and 
the cultured MSCs are descendants of periendothelial cells (Caplan 2008; da 
Silva Meirelles et al. 2008). 
MSCs are a heterogeneous population of cells containing just a small 
proportion of cells with stem cell characteristics. MSCs are defined as having 
certain characteristics. The minimal criteria defined by the ISCT (Dominici et 
al. 2006) are that these cell should be positive for CD90, CD73, and CD105 
and negative for hematopoietic lineage cell surface markers such as CD34, 
CD14, CD45, CD19, and HLA-DR (see Table 1). They ought to have the 
capacity to differentiate into adipocytes, chondrocytes, and osteoblasts and 
they must be plastic adherent. These criteria were established as markers for 
human BM-derived and fetal bovine serum (FBS) cultured MSCs and were 
set as a basis for additional characterization. Other markers commonly 
expressed on MSCs derived from different tissues are the molecules CD13, 
CD29, CD44, CD166, and HLA I (Hass et al. 2011; Lv et al. 2014), see Table 1.  
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 Cell surface markers commonly identified in MSCs and their expression on other Table 1.
 cell types. 
Cell surface 
protein 
activity/function expression on other cells expression 
on MSCs 
CD13 zinc 
metalloproteinase 
fibroblasts, endothelial cells, 
granulocytes, monocytes and 
mast cells 
+ 
CD14 receptor for 
endotoxin (LPS) 
macrophages, monocytes, 
granulocytes, dendritic cells and 
B-cells 
- * 
CD19 signal 
transduction 
molecule 
B cells and follicular dendritic 
cells -* 
CD29 cell adehesion 
molecule (integrin 
β-1) 
fibroblasts, platelets, T cells, 
monocytes, granulocytes, mast 
cells, endothelial cells and 
myoepithelial cells 
+ 
CD34 cell-cell adhesion 
factor 
hematopoietic stem and 
progenitor cells -* 
CD44 involved in cell-
cell interactions, 
cell adhesion and 
cell migration 
on most mammalian cell types 
+ 
CD45 tyrosine 
phosphatase 
hematopoietic cells -* 
CD49e integrin alpha 5 
subunit (join with 
β-1 unit) 
T cells, thymocytes, B cells, 
platelets, monocytes and 
neutrophils 
+ 
CD73 5'-nucleotidase T cells, B cells, follicular dendritic 
cells, epithelial cells and 
endothelial cells 
+* 
CD90 cell-cell and cell-
matrix 
interactions 
hematopoietic stem cells, 
neurons, fibroblasts, thymocytes, 
follicular dendritic cells, lymph 
node HEV endothelium 
+* 
CD105 regulatory 
component of  
TGF-β receptor 
endothelial cells, activated 
monocytes and tissue 
macrophages, pre B cells 
+* 
CD166 adhesion 
molecule 
neurons, activated T cells, 
activated monocytes, epithelium, 
fibroblasts 
+ 
HLA-ABC major 
histocompatibility 
complex class I 
all nucleated cells and platelets 
+ 
HLA-DR major 
histocompatibility 
complex class II 
B cells, T cells, monocytes, 
macrophages and NK cells -* 
 
* criteria according to ISCT 
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 FUNCTIONAL MECHANISMS OF MSCs 1.2.1
Beside the tri-lineage differentiation capacity of the MSCs described above, 
these cells have been demonstrated to have several other capabilities. These 
capabilities include the diverse plasticity to differentiate, the capacity to 
support the growth and differentiation of stem and progenitor cells 
(especially HSCs), the immunosuppressive and the angiogenic supporting 
capacity of the cells and the anti-apoptotic effects on other cells (Bronckaers 
et al. 2014; da Silva Meirelles et al. 2009). The mechanisms behind MSCs’ 
functioning in cell therapies can be divided into two categories: permanent 
cell replacement and soluble factor mediated mechanisms (see Figure 2). 
 
 Functional mechanisms of MSCs. MSCs have the capacity to differentiate into Figure 2
 different cell types at least in vitro. This capacity has been employed in permanent 
 cell replacement in tissue repair. The regenerative benefits of MSCs have been 
 demonstrated to be mainly consequences of the secreted factors.  
1.2.1.1 Tissue repair by cell replacement and differentiation 
MSCs have been demonstrated to have the capacity to differentiate, at least 
in vitro, into mesodermal, endodermal and ectodermal lineages. Besides the 
osteogenic, chondrogenic, and adipogenic differentiation, mesodermal 
differentiation into skeletal muscle, tendon, myocardium, smooth muscle, 
and endothelium has been demonstrated (Dezawa et al. 2005; Kuo and Tuan 
2008; Makino et al. 1999; Oswald et al. 2004; Ross et al. 2006). The 
ectodermal and endodermal differentiation into epithelial cells, neurons, and 
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hepatocytes has been shown to occur in certain conditions (Lee et al. 2004a; 
Spees et al. 2003; Woodbury et al. 2000). However, the non-mesodermal 
differentiation of the cells is controversial and it has not been demonstrated 
convincingly in vivo (Strioga et al. 2012). Some of the in vivo trans-
differentiation observations on MSCs have been shown to be due to the 
fusion of the MSCs with the contacted cells, and not via differentiation of 
MSCs (Alvarez-Dolado et al. 2003). Thus, the in vitro differentiation 
potential of MSCs does not necessarily correlate with the in vivo 
differentiation potential of the cells. 
Due to the in vitro differentiation capacity of MSCs, it was initially 
hypothesized that the differentiation capacity of MSCs would be the curative 
mechanism of these cells in tissue regeneration/engineering. It was 
envisioned that the transplanted cells would directly replace the damaged 
tissue. Later on, the regenerative benefits of MSCs have been demonstrated 
to be mainly a consequence of the paracrine mechanisms of MSCs, rather 
than a result of their differentiation (Bronckaers et al. 2014; Noiseux et al. 
2006; Togel et al. 2005). In tissue engineering, such as in repair of extensive 
bone defects, MSCs have been successfully used when seeded into scaffolds 
yielding a 3D bioimplant (Quarto et al. 2001; Sandor et al. 2014). The soluble 
factors secreted by MSCs together with osteoconductive biomaterials have 
shown to synergistically favor the production of good constructs (Wolff et al. 
2013). 
1.2.1.2 Secreted soluble factors 
 
Immunomodulation 
The discovery of the immunosuppressive capacity of MSCs has provided a 
potential tool for down-regulating the unwanted immune reactions. As MSCs 
do not express cell surface MHC II molecules without stimulation and they 
do not express co-stimulatory molecules CD80, CD86, or CD40 (Tse et al. 
2003), they are often said to be immune privileged. Nowadays it is, however, 
known that also MSCs are recognized by the host immune system and they 
may stimulate the immune cells (Ankrum et al. 2014). MSCs have been 
demonstrated to induce the proliferation of allogenic unstimulated 
lymphocytes (Karlsson et al. 2012; Le Blanc et al. 2003b) and the production 
of antibodies by B cells (Rasmusson et al. 2007; Traggiai et al. 2008). 
Allogenic MSCs have also been shown to cause a rejection of BM transplant if 
co-transplanted to sub-lethally irradiated mice. They can also induce a 
memory T cell response (Nauta et al. 2006). Thus, MSCs should be called 
“immune evasive”, rather than immune privileged (Ankrum et al. 2014). 
MSCs are able to suppress many types of immune cells of the innate and 
adaptive immune system. The overall picture of how MSCs influence the 
immune system is not yet clear, but an enormous number of different 
possible factors and mechanisms functioning via both soluble and cell 
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contact-dependent interactions have been demonstrated to be responsible 
for the immune modulatory effects. Several of the factors are listed in table 2. 
Contact dependent mechanisms such as PD-1 – PD-L1/2, Jagged1-Notch1, 
and Fas-Fas-L interactions in T and B cells have also been implicated 
(Akiyama et al. 2012; Augello et al. 2005; Liotta et al. 2008) 
MSCs may influence the activation, differentiation, proliferation, and the 
cytokine production of T cells, B cells, NK cells, DCs, and macrophages via 
diverse mechanisms. MSCs have been shown to influence the expression of 
co-stimulatory molecules on antigen presenting cells (Beyth et al. 2005). 
They have also been demonstrated to inhibit the degranulation of mast cells 
(Brown et al. 2011) and there are indications that they influence the 
apoptosis of immune cells (Glenn and Whartenby 2014). As MSCs promote 
the macrophage polarization into the immunosuppressive M2 subset (Cho et 
al. 2014; Francois et al. 2012; Kim and Hematti 2009), they influence the 
creation of anti-inflammatory milieu and thus also reduce the migration of 
inflammatory cells to the site of tissue damage. 
The immunosuppressive effects of MSCs have mostly been studied with T 
cells (van den Akker et al. 2013). Studies have shown that the suppressive 
effect of MSCs on T cell proliferation is enhanced when MSCs are pre-
exposed to effector cytokines such as interferon gamma (IFNγ), TNFα, and 
interleukin (IL)-1β (Chang et al. 2006a; Le Blanc et al. 2003a; Ren et al. 
2008). Besides their suppressive effect on the proliferation of T cells, MSCs 
also suppress the IFNγ production of Th1 cells and promote the secretion of 
IL-4 by Th2 cells, while also increasing the amount of regulatory Tregs 
(Aggarwal and Pittenger 2005; English et al. 2009). 
MSCs have been reported to express several toll-like receptors (TLRs) 
(Delarosa et al. 2012; van den Akker et al. 2013) and the activation of these 
innate immune system associated receptors may contribute to the 
polarization of MSCs into an anti- or pro-inflammatory phenotype 
(Waterman et al. 2010). Although, as there are many conflicting results 
regarding the effects of TLRs (Munir and McGettrick 2015), more research 
will be necessary to clarify their role in MSC immunomodulation properties.  
Extracellular nucleotides (such as ATP, ADP, UTP, and UDP) are 
mediators of intercellular communications in virtually all tissues and they are 
important factors in cell stress (Burnstock 2006). These nucleotides are 
degraded into nucleosides, such as adenosine (Ado). Ado is found in every 
tissue and organ and it regulates their function. It has an important role in a 
wide variety of biochemical processes such as energy transfer and it also acts 
as an inhibitor in presynaptic excitatory neurotransmitter release (Borea et 
al. 2016). Ado mediates cardioprotective, neuroprotective, vasodilatatory, 
and angiogenic responses and it counteracts the inflammatory/stress signal 
triggered by adenosine triphosphate (ATP) (Scarfi 2014). Ado is either 
released directly by cells or generated by de-phosphorylation of adenine 
nucleotides. This de-phosphorylation is performed by two ectonucleotidases, 
CD39 and CD73 (Scarfi 2014). The CD39 CD73 mediated adenosinergic 
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pathway has been demonstrated to be an important machinery used by Tregs 
to inhibit T cell proliferation and cytokine secretion (Deaglio et al. 2007). 
Recently this pathway has also been shown to have a relevant function in 
MSCs, as demonstrated with mice MSCs (Sattler et al. 2011). Chen et al. 
demonstrated that human gingiva-derived MSCs suppress the proliferation 
of murine CD4+CD25- T cell proliferation via the CD39 CD73 pathway (Chen 
et al. 2013). Recently, Amarnath et al. demonstrated the Ado signalling to be 
responsible for the therapeutic effect in a xenogeneic mouse GVHD model 
(Amarnath et al. 2015). The role of MSCs’ Ado pathway has also been 
indicated in autoimmune responses in experimental autoimmune uveitis 
model in mice (Chen et al. 2016). Also, in vitro studies showing that human 
MSCs impact the suppression of human T cell functions via the Ado pathway 
have been published (Chen et al. 2016; Lee et al. 2014; Saldanha-Araujo et al. 
2011). 
As there are many different mechanisms behind the immunomodulatory 
effects of MSCs, it is most probable that a combination of different pathways 
will provide the optimal effect in each certain situation. 
 
Angiogenesis supporting effects 
Angiogenesis means the formation of new blood vessels from the pre-existing 
vasculature. Angiogenesis is a fundamental physiological event in the 
development of an individual and in wound and fracture healing (Bronckaers 
et al. 2014). Angiogenesis is a tightly regulated process initiated only in 
response to specific stimuli such as inflammation and hypoxia. The induction 
of endothelial cells to start a new branch of blood vessel requires the 
liberation of pro-angiogenic growth factors, such as vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), and stromal 
derived factor-1 (SDF-1). Angiogenic factors are naturally released during the 
proteolytic breakdown of extracellular matrix (ECM) of the capillaries 
(Bronckaers et al. 2014). MSCs secrete numerous angiogenic factors (Table 
2) including VEGF, bFGF, placental growth factor (PLGF), monocyte 
chemoattractant protein-1 (MCP-1), IL-6, and insulin like growth factor-1 
(IGF-1) (da Silva Meirelles et al. 2009). 
Studies have shown that various conditions and factors have an impact on 
the capacity of MSCs to secrete angiogenic factors. It has been demonstrated 
that the induction of MSCs with chemokines and growth factors, such as 
transforming growth factor (TGF)-α and angiotensin II, induce the MSCs to 
secrete several angiogenic factors. Additionally, the conditioned medium 
(CM) of the induced cells is more efficient in supporting angiogenesis than 
the CM of non-treated MSCs (De Luca et al. 2011; Liu et al. 2015). According 
to studies, the angiogenic supporting capacity of MSCs is also enhanced by 
hypoxic environment (Aranha et al. 2010; Chen et al. 2008). In addition, 
serum-deprivation has been shown to increase the capacity of MSCs to be 
angiogenic (Oskowitz et al. 2011). 
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Studies have shown MSCs to be involved in all steps of angionenesis in 
vitro. They induce endothelial cell proliferation, migration, invasion, and 
tube formation, and they have also been indicated to protect endothelial cells 
from apoptosis (Bronckaers et al. 2014). The capacity of MSCs to stabilize the 
newly formed vessels in a manner similar to pericytes has supported the 
pericyte theory (Caplan and Correa 2011). Besides the secretion of angiogenic 
factors, MSCs have also been demonstrated to differentiate into endothelial 
cell-like cells at least in vitro (Oswald et al. 2004), and this differentiation 
can be induced by several treatments of MSCs (Bekhite et al. 2014). 
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 Soluble factors secreted by MSCs (non-comprehensive) Table 2.
Factors in Targets References 
immunomodulation   
Idoleamine-2,3-
oxygenase (IDO) 
T cells, macrophages, 
NK cells 
(Francois et al. 2012; Meisel et 
al. 2004; Spaggiari et al. 2008) 
 
prostaglandin E2 
(PGE2) 
macrophages, DC, T 
cells, Mast cells, NK 
cells 
(Aggarwal and Pittenger 2005; 
Brown et al. 2011; Spaggiari et 
al. 2008) 
 
IL-6 neutrophils, DC, 
macrophages 
(Djouad et al. 2007; Raffaghello 
et al. 2008; Zhang et al. 2010) 
GM-CSF macrophages (Zhang et al. 2010) 
IL-10 T cells  (Qu et al. 2012) 
TGF- β1 Treg (Patel et al. 2010) 
Nitric oxide (especially in 
mice) 
T cells (Shi et al. 2011) 
heme oxygenase-1 T cells (Chabannes et al. 2007) 
HLA-G5 T cells (Selmani et al. 2009) 
Galectin-3 T cells (Sioud et al. 2010) 
Adenosine (Ado) T cells (Saldanha-Araujo et al. 2011) 
angiogenesis and growth support  
VEGF endothelial cells (Kinnaird et al. 2004; Rehman et 
al. 2004) 
IGF-1 endothelial cells (Togel et al. 2007) 
bFGF endothelial cells (Kinnaird et al. 2004) 
PLGF induction of vessel 
formation 
(Kinnaird et al. 2004) 
IL-6 endothelial cells (Zhang et al. 2013) 
MCP-1 endothelial cells (Boomsma and Geenen 2012) 
SDF-1 hematopoietic 
stem/progenitor cells 
(Van Overstraeten-Schlogel et 
al. 2006) 
angiopoietin 1 endothelial cells (Wu et al. 2007) 
anti-apoptosis   
VEGF endothelial cells (Rehman et al. 2004; Togel et al. 
2007) 
HGF endothelial cells (Rehman et al. 2004; Togel et al. 
2007) 
IGF-1 endothelial cells (Togel et al. 2007) 
stanniocalcin 1 epithelial cells, 
fibroblasts 
(Block et al. 2009) 
TGF- β endothelial cells, 
cardiomyocytes 
(Rehman et al. 2004; Wang et al. 
2009) 
bFGF endothelial cells (Rehman et al. 2004) 
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Extracellular vesicles 
Besides the secretion of soluble molecules such as immunomodulatory and 
angiogenic factors, MSC have been described to secrete extracellular vesicles 
(EVs), subtyped as microvesicles (MVs) and exosomes. MVs are generated by 
budding of the cell membrane and they are 50 nm - 1,000 nm in size. 
Exosomes, which were originally thought a by-product of cell turnover, are 
slightly smaller (40-100 nm) or of the same size. Exosomes are thought to be 
of endosomal origin and to have homogenous characteristics with defined 
biophysical and biochemical properties, e.g. the constitution of their lipid 
membrane is well characterized (Madrigal et al. 2014; Rani et al. 2015). The 
types of different vesicles are not clearly defined and thus the nomenclature 
of these vesicles is confusing and the same term can mean different things to 
different investigators. It has been suggested that while there is no consensus 
about the nomenclature, the preferred term for these vesicles would be EVs 
(Gould and Raposo 2013). 
EVs can be collected from all types of body fluids and also from cell 
culture supernatants. EVs facilitate the communication between cells by 
transferring bioactive molecules and they are involved in normal 
physiological processes. Liberated EVs may be internalized by other cells via 
endocytosis or cell type specific phagosytosis. Extracellular signals, such as 
hypoxia and inflammation, have been demonstrated to regulate the protein 
packing into EVs and their release from MSCs (Rani et al. 2015). EVs may 
also have a role in the development and progress of diseases. EVs have been 
linked to tumorigenesis, spread of viruses and pathogenic agents. In 
addition, factors involved in neurodegenerative diseases have been 
associated with EVs (Iraci et al. 2016). 
The advantageous effect of MSC-derived EVs (MSC-EV) on several 
diseases has been demonstrated in several animal models. There is also 
evidence from animal models that points to their beneficial role in cutaneous 
wound healing and in the healing of myocardial infraction, acute kidney 
injury (AKI), liver diseases, and lung diseases (Arslan et al. 2013; Bruno et al. 
2009; Kilpinen et al. 2013; Li et al. 2013; Timmers et al. 2007; Zhang et al. 
2015; Zhu et al. 2014). MSC-EVs have also been demonstrated to have 
immunomodulatory capacities (Mokarizadeh et al. 2012) and anti-tumor 
activities, and their role in drug delivery has also been studied (Pascucci et al. 
2014; Wu et al. 2013).  
In animal models, MSC-EVs have been shown to specifically accumulate 
in the site of injury (Grange et al. 2014). This has also been seen with MSCs, 
although they are, at least first, trapped in the lungs when administered 
intravenously (Gao et al. 2001; Kerkela et al. 2013; Mahmood et al. 2003; 
Nystedt et al. 2013; Schrepfer et al. 2007). Amarnath et al. have shown that 
MSCs trapped in the lungs deliver their systemic immune suppression via 
MSC-EVs (Amarnath et al. 2015). There has also been a case study with 
MSC-EVs administrated to a human to treat GVHD and the results indicated 
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that MSC-EVs may have potential for the treatment of GVHD (Kordelas et al. 
2014). 
One of the mechanisms behind the beneficial effects of MSC-EVs has been 
suggested to be the delivery of mRNA and miRNA (Chen et al. 2010; 
Tomasoni et al. 2013). Other forms of biological information transmitted by 
EVs include proteins, glycoproteins, and lipids. MSC-EVs are hypothesized to 
have advantages over MSCs in clinical use in the future (Rani et al. 2015).  
 TISSUE SOURCES 1.2.2
MSCs have been derived from many different tissues. The most well 
characterized MSCs are BM-derived MSCs (BM-MSCs). Other, well 
characterized MSC sources include adipose tissue (AT)1, cord blood (CB), 
umbilical cord (UC), and placenta (Mattar and Bieback 2015). The afterbirth 
(such as placenta and umbilical cord) is considered a good source of MSCs as 
these tissues are abundantly available and would otherwise be biological 
waste. Also, excess AT removed by liposuction is a medical waste and is thus 
available for other uses (Strioga et al. 2012). The collection of BM is an 
invasive procedure which always contains a risk of infection (Hass et al. 
2011), making alternative sources to bone marrow very attractive.  
All MSCs are not equal and MSCs from different tissues vary. The cells are 
in principal similar, but some variance is seen in their differential 
proliferation potential, surface marker expression, and functional capacities. 
Also, the gene expression profiles of MSCs from different tissues have been 
shown to have significant differences between different tissues (Wagner et al. 
2005).  Along with AT-MSCs, the initial CFU-F numbers are described as the 
highest, as compared to BM- and CB-derived MSCs (CB-MSCs) (Kern et al. 
2006). Although the initial number of MSC in CB is very low, the 
proliferative capacity of CB-MSCs and other afterbirth tissue-derived MSCs 
is reported to be higher than that of MSCs from adult tissues (Barlow et al. 
2008; Kern et al. 2006). An example of the variance in the 
immunophenotype of MSCs from different tissues is the CD34 positivity of  
AT-MSCs, reported at least at early stages in vitro (Maumus et al. 2011; 
Traktuev et al. 2008), whereas MSCs from other sources are negative for this 
marker (see Table 1). Variance in the differentiation capacities has been 
observed among MSCs from different sources. CB-MSCs are reported to 
differentiate poorly into adipocytes in vitro (Bieback et al. 2004; Chang et al. 
2006b; Manca et al. 2008; Montesinos et al. 2009; Yoshioka et al. 2015; 
Zhang et al. 2011), while in vivo it has been shown that dental pulp derived 
MSCs differentiate into dentin and not into bone as do similarly handled BM-
                                                 
1 AT-derived MSCs (AT-MSCs) are named with a variety of names and the name adipose derived 
stem/stromal cells (ASC) is currently the most accepted term for these cells (Lindroos et al. 2011). 
These cells are however named AT-MSCs in this thesis to indicate their similarity with MSCs from 
other sources. 
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MSCs (Gronthos et al. 2000). The capacity of MSCs to support the 
construction of functional  hematopoietic niche has recently been shown to 
be restricted to BM-derived MSCs, as opposed to AT-MSCs and umbilical 
cord-derived MSCs (UC-MSCs) (Reinisch 2015). 
The comparison of immunomodulatory capacities of MSCs from different 
tissues has been reviewed by Mattar and Bieback (2015). Although it has 
been reported that MSCs from all tested sources are capable of suppressing 
immune reactions in vitro there is some variability in their capacities (Mattar 
and Bieback 2015). In many studies, AT-MSCs, for instance, have been 
demonstrated to have enhanced immunosuppressive capabilities compared 
to BM-MSCs, though conflicting results also exists. The heterogeneity in the 
experimental protocols makes it difficult to compare the immunosuppressive 
capabilities of MSCs from different sources (Mattar and Bieback 2015).  The 
angiogenic supporting potential of MSCs has also been described to vary 
between different sources. AT-MSCs have been demonstrated to have 
significantly greater angiogenic potential than BM-MSCs (Kim et al. 2007). 
As these results are to some extent conflicting and most of the comparative 
studies have been conducted in vitro, the real difference in the capacities of 
MSCs from different sources still needs to be studied further to establish 
whether one source is more beneficial than another in therapy. 
 CLINICAL USE OF MSCs AND CLINICAL TRIALS  1.2.3
The basis for using MSCs for clinical purposes relies on their immune 
regulation capacity, hematopoiesis, and tissue regeneration supporting 
functions, as well as on their migratory capacity. Numerous promising in 
vitro studies with animal models have rapidly made MSCs a major focus of 
cell-based therapies (see Figure 1). 
In the first trials, autologous MSCs were utilized in the treatment of 
patients suffering from hematological malignancies, without any indications 
of adverse effects (Lazarus et al. 1995). Osteogenesis imperfect was the first 
disease treated with allogenic MSCs in a clinical study (Horwitz et al. 2002). 
The effects of allogenic MSCs have also been studied in a clinical trial with 
patients with inborn metabolic errors (Koc et al. 2002). Although the clinical 
results of the first trials did not clearly demonstrate the efficacy of MSCs they 
were important as they provided preliminary evidence that MSCs can be 
administered without adverse effects, indicating the safety of MSC therapy 
(Singer and Caplan 2011). 
Since then, the number of clinical trials has increased enormously, with 
the number of completed or ongoing clinical trials being nearly 350 in 2013 
(Ankrum et al. 2014), and rising close to 500 in 2015 (Squillaro et al. 2016). 
The current number of clinical trials is 652 including completed, terminated, 
and ongoing studies (data from clinicaltrials.gov, March 2016, with search 
terms “Mesenchymal Stem cells”, “Mesenchymal Stromal Cells”, 
“Multipotent stromal cells”, and “bone marrow stromal cells”). Most of the 
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clinical trials occur, at an early phase, which demonstrates that the 
therapeutic effectiveness still needs to be proven. Based on the first 
systematic review and meta-analysis that comprehensively summarizes the 
safety of systemic MSC administration, this therapy appears to be safe (Lalu 
et al. 2012). The long term safety of MSC based cell therapies is still poorly 
investigated, which hinders the translation of these therapies into clinical 
practice (Squillaro et al. 2016). 
GVHD is an adverse condition where the transplanted cells attacks host 
tissues and organs and it occurs in 30-80% of recipients after allogeneic 
hematopoietic stem cell transplantation (Squillaro et al. 2016). The capacity 
of MSCs to treat GVHD has been extensively studied since the first case study 
reported by Le Blanc et al. in 2004 (Le Blanc et al. 2004). Data from most 
studies suggest that MSCs are effective for GVHD (Ankrum et al. 2014; 
Sharma et al. 2014; Squillaro et al. 2016), although also conflicting data 
exists (Parekkadan and Milwid 2010; von Bonin et al. 2009). Besides GVHD, 
MSCs have been used to treat several other diseases and conditions including 
cardiovascular diseases, neurologic diseases, autoimmune diseases, organ 
transplantation, wound healing, and defects in bone and cartilage (Table 3). 
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 Examples of reported clinical trials and pilot studies with MSCs Table 3.
target of therapy MSC type Reference 
supporting function 
HSC transplantation 
autologous BM-MSC, 
HLA-
identical/haploidentical-
related BM-MSC 
(Macmillan et al. 2009; 
Meuleman et al. 2009) 
GVHD allogenic BM-MSCs, 
identical/haploidentical-
related BM-MSC, 
allogenic AT-MSCs 
(Arima et al. 2010; Fang et al. 
2007; Kebriaei et al. 2009; Le 
Blanc et al. 2004; Le Blanc et 
al. 2008; Ringden et al. 2006; 
Zhao et al. 2015) 
stroke autologous BM-MSC (Bang et al. 2005; Honmou et 
al. 2011; Lee et al. 2010) 
myocardial infarction allogenic/autologous 
BM-MSC 
(Chen et al. 2004; Hare et al. 
2009; Mohyeddin-Bonab et 
al. 2007; Yang et al. 2010) 
kidney 
transplantation 
allogenic AT-MSCs, 
autologous BM-MSC 
(Perico et al. 2011; Vanikar et 
al. 2011) 
chronic obstructive 
pulmonary disease 
(COPD), 
allogenic BM-MSCs (Weiss et al. 2013) 
osteogenesis 
imperfecta 
allogenic BM-MSCs (Horwitz et al. 2002) 
cartilage lesions autologous BM-MSC (Wakitani et al. 2011) 
wound healing  autologous BM-MSC (Falanga et al. 2007) 
liver diseases autologous BM-MSC, 
allogenic UC-MSC 
(Kharaziha et al. 2009; 
Mohamadnejad et al. 2007; 
Zhang et al. 2012) 
Crohn’s disease allogenic BM-MSCs 
autologous AT-MSCs, 
autologous BM-MSC 
(de la Portilla et al. 2013; 
Duijvestein et al. 2010; 
Garcia-Olmo et al. 2005; 
Liang et al. 2012)  
 
inborn metabolic 
disorders 
allogenic BM-MSCs (Koc et al. 2002)  
systemic lupus 
erythematosus (SLE) 
allogenic UC-MSC, 
allogenic BM-MSC  
(Liang et al. 2010; Sun et al. 
2010) 
multiple sclerosis autologous BM-MSC (Karussis et al. 2010; Llufriu 
et al. 2014) 
Parkinson’s disease autologous BM-MSC (Venkataramana et al. 2010) 
amyotrophic lateral 
sclerosis (ALS) 
autologous BM-MSC (Karussis et al. 2010; Kim et 
al. 2014; Mazzini et al. 2003) 
spinal cord injury autologous AT-MSCs (Ra et al. 2011) 
cerebral palsy (CP) autologous BM-MSC (Wang et al. 2013) 
 
It has also been suggested that because of their capacity to migrate to 
tumour environment, MSCs may be useful as cellular vehicles for targeted 
delivery of chemotherapeutics into tumours (Adjei and Blanka 2015). Virus 
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transduced MSCs have already been used in clinical studies to deliver tumour 
destroying virus into tumours such as neuroblastoma (Garcia-Castro et al. 
2010). Although MSCs themselves are not shown to be tumorigenic, (Tarte et 
al. 2010) their tumour migrating capacity and immunosuppressive effects 
may also be a threat in a case that the recipient has an un-known tumour 
when treated with MSCs. In animals with a pre-existing tumour, MSCs have 
been shown to promote tumour growth (Djouad et al. 2006). Thus, there are 
still several issues to resolve before all the potential held by MSCs and their 
possible adverse effects in clinical settings are known. 
1.3 CULTURE OF MSCs 
There are several methods for culturing MSCs. The beginning of the culture 
usually starts with the isolation of mononuclear cells (MCs) when using 
tissues such tissues as BM, CB, or peripheral blood as starting material. 
These sources do not need to be mechanically or enzymatically treated, as do 
such sources as adipose tissue, placenta, and umbilical cord (Dehkordi et al. 
2015; Gimble and Guilak 2003; Parolini et al. 2008). MSC cultures have also 
been established by enriching first certain cell populations using magnetic 
selection (Tondreau et al. 2005; Zhang and Chan 2010). Although these 
selections may enrich MSCs, the resulting cell populations are still 
heterogeneous and the majority of the isolated cells do not give rise to CFU-F 
(Ho et al. 2008).  
Cell isolation is followed with plating of the cells. Cells are most often 
plated on uncoated culture flasks made of plastic or on flasks coated with a 
protein, usually extracellular matrix protein (Ho et al. 2008). MSCs are 
assumed to adhere within a few days after initial plating, and the following 
media changes remove the contaminating non-adherent hematopoietic cells 
(Bara et al. 2014). It has been suggested that the variation between groups in 
these initial culture procedures may result in differences in the outcome of 
MSC cultures and the following cell-based therapies conducted with these 
cells (Bara et al. 2014). 
Also seeding density and confluency of cultures have been shown to 
impact the properties of MSCs. MSCs seeded at low density have been shown 
to have the highest capacity to proliferate (Both et al. 2007; Colter et al. 
2000). It has also been demonstrated that if MSC cultures are grown to 
confluence, the proliferative capacity of the cells is diminished (Lennon et al. 
2012). In contrast, the effect of culturing MSCs to their confluence does not 
affect their capacity to differentiate (Lennon et al. 2012). Ylöstalo et al. have 
shown that MSCs in the middle of a dense cell colony are partially 
differentiated, compared to cells in the outer part of the colony. This 
difference can be reversed when the cells are re-plated. When re-plated at 
clonal densities, the cells from the outer and inner part of the initial colony 
become indistinguishable (Ylostalo et al. 2008). Thus the sub-culturing of 
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MSCs on a regular basis seems to be important when propagating these cells 
(Lennon et al. 2012). 
Culture conditions have been shown to impact the properties of MSCs. 
Many of the cell preparations given different names may just be creations of 
the conditions they have been cultured in. Roobrouck et al. demonstrated 
that MSCs and MAPCs have different properties that are at least partially 
mediated by culture conditions (Roobrouck et al. 2011a). Roobrouck et al. 
specifically showed that changing the MSC culture condition to MAPC 
culture condition shifted the MSC gene expression profile toward the MAPC 
gene expression profile and vice versa (Roobrouck et al. 2011a). Others have 
also demonstrated that different culture conditions change the gene 
expression profile of MSCs (Wagner et al. 2005) and it has been noted that 
slight experimental modifications can lead to the production of completely 
different cell population (Ho et al. 2008). 
 CULTURE MEDIA 1.3.1
MSCs have been cultured in a variety of different culture media. The basic 
media is most commonly DMEM/DMEM F12 or alpha MEM (Bara et al. 
2014), supplemented with various supplements. The glucose concentration 
used in MSC culture media is 1,000 mg/ml (5.5 mM) which approximates 
normal blood sugar levels in vivo.  This glucose concentration has been 
demonstrated to have better capacity to support MSC growth compared to 
the higher glucose concentration of 4,500 mg/ml (Sotiropoulou et al. 2006). 
Glutamine is an essential nutrient needed in cell culture. It is unstable, 
leading to formation of ammonia in cell cultures and finally to cell growth 
inhibition. The use of GlutamaxTM (dipeptide L-alanine-L-glutamine) 
provides L-glutamine in a more stable form and it has proved to have better 
capacity to support the growth of MSCs (Sotiropoulou et al. 2006) than the 
use of L-glutamine.  For successful cell culture, a mixture of factors for cell 
attachment, growth, and proliferation is also needed. FBS is the most 
common supplement containing these essential factors in MSC cultures. 
MSCs cultured from different sources seem to have different needs regarding 
the medium. In their studies, Wagner et al. noticed that MSCs from CB could 
not be obtained using the same low serum conditions with few additives as 
for BM-MSCs (Wagner et al. 2005). CB-MSCs seem to need more FBS or 
other supporting components in the medium (Kogler et al. 2004). Different 
supplements have been used to enhance the growth of MSCs; some of these 
are listed in table 4.  
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 Growth supporting factors used in MSC culture media Table 4.
growth factor cell type reference 
bFGF CB-MSC, BM-MSC 
(Gharibi and Hughes 
2012; Jung et al. 2010; 
Lee et al. 2004b; Ng et al. 
2008; Zhang et al. 2011) 
platelet derived growth 
factor-BB (PDGF-BB) 
BM-MSC 
(Gharibi and Hughes 
2012; Ng et al. 2008) 
epidermal growth factor 
(EGF) 
BM-MSC 
(Gharibi and Hughes 
2012) 
dexamethasone (DX) CB-MSC, BM-MSC 
(Xiao et al. 2010; Zhang et 
al. 2011) 
TGF-β BM-MSC (Jung et al. 2010; Ng et al. 
2008) 
stem cell factor (SCF) CB-MSC (Zhang et al. 2011) 
ascorbic acid BM-MSC 
(Gharibi and Hughes 
2012; Jung et al. 2010) 
Wnt3 BM-MSC (Gharibi and Hughes 2012) 
IL-3 CB-MSC (Zhang et al. 2011) 
 
1.3.1.1 FBS and its substitutes 
FBS has been the most commonly used supplement in MSC culture media. 
The concentration of FBS varies from 2% up to 30% (Kogler et al. 2004; 
Pittenger et al. 1999; Reyes et al. 2002), 10% being the most common 
concentration. Although FBS supports the MSC growth well, there are several 
disadvantages associated with it, one being the huge lot-to-lot variation 
(Tekkatte et al. 2011).  The major disadvantages pertain to the safety of using 
FBS for culturing cells for clinical purposes. Animal-derived components 
hold the risk of possible contamination with viruses, bacteria, mycoplasma, 
yeast, fungi, and endotoxins (Tekkatte et al. 2011). It has also been 
demonstrated that FBS cultured MSCs may induce antibody production 
against FBS when administered to patients (Horwitz et al. 2002; Sundin et 
al. 2007). 
For clinical purposes the use of xeno-free culture conditions are 
encouraged by regulators. The term xeno-free means a product that does not 
contain any animal-derived components. Several different substitutes for 
FBS have been tested (listed in Table 5). These medium supplements include 
human serum, plasma, CB serum, and platelet derivatives (Tekkatte et al. 
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2011). Although chemically defined medium would be the optimal solution, 
the design of the composition of the medium is extremely challenging since 
the effect of individual growth factors on MSC growth is poorly understood 
(Tekkatte et al. 2011). Platelet lysate (PL), which is derived from platelet rich 
plasma (PRP), has been the most studied FBS substitute and it is an 
acceptable medium supplement according to regulators (Wuchter et al. 
2015). The use of PL instead of FBS does not necessarily make the culture 
medium xeno-free as porcine-derived heparin is usually needed to prevent 
the clotting of coagulation factors-containing PL. The use of heparin has been 
accepted as it is an approved pharmaceutical.  Heparin-free medium using 
serum converted PL instead PL containing coagulation factors has also been 
demonstrated to support MSC growth (Mojica-Henshaw et al. 2013). In 
addition, a commercially available PL-product with reduced coagulation 
factors as a supplement in culture medium without heparin has already been 
tested in MSC cultures. The capacity of the coagulation factor reduced PL to 
support MSC growth might, however, be diminished (Juhl et al. 2016). 
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 Pros and cons of FBS substitutes tested in MSC cultures. Table 5.
FBS substitute + - reference 
autologous serum high proliferation rate 
diminished 
differentiation, 
limited availability 
(Shahdadfar et al. 
2005) 
allogenic serum 
expansion 
kinetics 
comparable 
with FBS at 
early passages 
inhibitory effects 
on growth and 
survival of MSCs 
and decelerated 
proliferation from 
p4 on 
(Bieback et al. 2009; 
Shahdadfar et al. 
2005) 
thrombin activated 
platelet lysate 
expansion 
kinetics 
comparable 
with FBS at 
early passages 
decelerated 
proliferation from 
p4 on, requires 
fresh preparation, 
complicate 
preparation 
(Bieback et al. 2009) 
PL (plasma- 
containing) 
high expansion 
rate, no lot-to-
lot variability 
need of porcine 
derived heparin (Bieback et al. 2009) 
serum converted PL 
heparin-free 
culture, 
proliferative 
capacity 
comparable to 
plasma-
containing  PL 
complicate 
preparation 
(Mojica-Henshaw et 
al. 2013) 
coagulation factor 
reduced PL 
(Stemulate TM) 
heparin-free 
culture 
diminished 
proliferation 
compared to PL 
(Juhl et al. 2016) 
CB/placental serum 
High expansion 
capacity, 
availability 
no attachment to 
plates after p3 
(Julavijitphong et al. 
2014; Shafaei et al. 
2011; Shetty et al. 
2007) 
 
 OXYGEN CONCENTRATION 1.3.2
In vitro culture of cells is usually performed in incubators in normal 
atmospheric oxygen (O2) concentration in the presence of 5% carbon dioxide 
(CO2). 5% CO2 is optimal for the maintenance of appropriate pH conditions 
and it resembles the CO2 concentration in vivo (Csete 2005; D'Ippolito et al. 
2006).  The O2 concentration is not usually controlled due to the more 
complicated controlling procedures as, besides the surrounding atmospheric 
O2 conditions, the O2 tension depends on the depth of medium, density of 
cells, and cellular respiration (Csete 2005). Thus the standard O2 
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concentration in incubators supplied by room air is 20% (Haque et al. 2013). 
The physiological O2 level is significantly lower. The O2 concentration varies 
from tissue to tissue, being 1% in cartilage and bone, 1-6% in BM and 4-14% 
in circulation, and 3-8% in placenta (Haque et al. 2013; Sullivan et al. 2006). 
It has been reported that the proliferation of stem cells is enhanced and 
their apoptosis is reduced in low O2 concentrations (Csete 2005). Also, the 
proliferation of MSCs has been demonstrated to be enhanced when cultured 
in low O2 concentrations (Carrancio et al. 2008; Dos Santos et al. 2010; 
Estrada et al. 2012; Tsai et al. 2011). Although low O2 concentrations enhance 
the proliferation of MSCs, this effect is only seen clearly at late passages 
(Fehrer et al. 2007; Tsai et al. 2011). Besides the supportive effect on the 
proliferation of MSCs, low O2 concentrations are also known to reduce the 
genetic instability and oxidative stress in MSCs (Estrada et al. 2012). 
A few reports propose that different cell populations are generated under 
low O2 concentrations. MIAMI cells have been cultured from BM in low O2 
concentrations on fibronectin (FN)-coated culture plates in the medium 
supplemented with 5% FBS. These cells have been reported to have extensive 
proliferative capacity and a wide in vitro differentiation repertoire 
(D'Ippolito et al. 2004). The same group also cultured MIAMI cells in 
different O2 concentrations (1%, 3%, 5%, 10%, and 21%) and noticed that the 
cells cultured in 3% O2 concentration have the highest capacity to proliferate 
(D'Ippolito et al. 2006). 
Buchheiser et al. reported that cells with different properties can be 
derived from CB in different O2 concentrations (5% and 20%) (Buchheiser et 
al. 2012). In 20% O2, they were able to generate both CB-MSCs and so called 
USSCs. USSCs are defined as differing from CB-MSCs by their Homeobox 
(HOX) gene expression pattern, Delta-like 1 homolog (DLK-1) expression, 
and by their adipogenic differentiation capacity (Kluth et al. 2010). HOX 
genes are known to be involved in tissue specification and cell identity during 
embryonic development and the HOX expression pattern of murine MSCs 
points to the topographic origin of the cells (Ackema and Charite 2008). The 
cells generated in 5% O2 concentrations differed from both CB-MSCs and 
USSCs (Buchheiser et al. 2012). They also showed that growth kinetics of the 
cells generated in 20% O2 concentration did not change when converted to 
5% O2 concentration. On the other hand, the cells generated in 5% O2 
concentration showed decreased proliferation capacity and they seemed to be 
less adaptive to higher O2 concentrations. Buchheiser et al. hypothesized that 
culture conditions during the generation of cells is more critical than 
temporary changes in O2 concentrations. Thus different cell populations may 
be generated at different frequencies depending on the O2 concentration 
(Buchheiser et al. 2012). 
An example of the influence of environmental conditions on the 
functionality of MSCs is the effect of hypoxia on these cells. With hypoxic 
(1%) O2 concentration, MSCs have been shown to increase the production of 
trophic factors to enhance angiogenesis and immune modulatory activity 
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(Madrigal et al. 2014). These examples indicate the responsiveness of MSCs 
to the surrounding environment. 
 CULTURE OF MSCs FOR CLINICAL USE 1.3.3
MSCs have been cultured from different sources in a variety of different 
conditions. Clinical trials are also conducted with MSCs produced with 
different culture protocols and consequently the data obtained from these 
trials may be difficult to interpret. A position paper written by researchers, 
clinicians, and regulators (Wuchter et al. 2015) gives recommendations and 
relevant information that promote the goal of having a common standard for 
the production of MSCs for clinical use. The paper presents 
recommendations that pertain to the source of MSCs, media composition, 
and duration of cell expansion, as well as recommendations for storage and 
measures of quality controls. As BM is the most commonly used source of 
MSCs, the position paper concentrates on this tissue. Xenogeneic-free 
medium with defined and certified ingredients is recommended, with PL 
recommended as the supplement for the medium. The duration of culture 
should be as limited as possible, counted by means of the population 
doubling (PD) numbers (Wuchter et al. 2015).  
For quality control testing, it is recommended that the MSCs should be 
positive for CD73, CD90, and CD105 and negative for CD45. Measuring other 
markers is recommended depending on the source of the cells and their 
therapeutic use (see Table 1). No recommendations can be given about 
measuring the immunomodulatory capacity of MSCs as the existing in vitro 
assays do not necessarily reflect their in vivo capacity. Although there is no 
indication of adult MSCs having tumorigenic potential, the occurrence of 
chromosomal abnormalities should be checked by karyotyping. The 
monitoring of PD time is recommended to help to detect highly proliferating, 
possibly transformed cell populations (Wuchter et al. 2015). 
1.3.3.1 Regulation and good manufacturing practice (GMP) 
Culture expanded MSCs are classified as advanced therapy medicinal 
products (ATMPs) according to EU legislation (Regulation (EC) 1394/2007 
on advanced therapy medicinal products). Subclasses of ATMPs include gene 
therapy medicinal products (GTMPs), somatic cell therapy medicinal 
products (sCTMPs), and tissue engineered medicinal products (TEPs) (Celis 
et al. 2015). CTMPs and TEPs, also referred to as cell-based medicinal 
products (CBMPs), differ from cell and tissue transplants as they have 
undergone additional manipulation and they can be used for a function in 
the recipient that differs from the original function in the donor (Celis et al. 
2015). MSCs belong to the group of sCTMPs. 
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As ATMPs are complex pharmaceuticals, a risk-based approach has been 
developed to enhance the regulatory flexibility needed for the regulation of 
these products (Celis et al. 2015). The Committee for Advanced Therapies 
(CAT) within the European Medicines Agency (EMA) is responsible for all 
regulatory procedures concerning ATMPs in the EU (Ancans 2012). It offers 
classification, certification, and evaluation procedures concerning ATMPs, 
and thus also all regulatory procedures for MSCs. CAT reviews the quality, 
safety, and efficacy of ATMPs prior to marketing authorization. After 
authorization, ATMPs are subject to a strict post-authorization surveillance 
program to ensure the patient safety (Celis et al. 2015). Alternatively, an 
ATMP therapy product may be considered for a national authorized 
procedure under the hospital exemption. For hospital exemption 
authorization, the product has to be prepared on a non-routine basis 
according to specific quality standards, and it has to be used within the same 
Member State in a hospital under the exclusive professional responsibility of 
a medical practitioner (Ancans 2012). The national authorities (in Finland 
Finnish Medicines Agency) have a crucial role in the supervision of clinical 
trials of ATMPs as well as the supervision of hospital exemptions. 
Prior to clinical studies, non-clinical studies are mandatory for the 
assessment of risks related to a new ATMP. Non-clinical studies should be 
performed in relevant animal models to demonstrate the proof of principle 
for the product and to define the pharmacological and toxicological effects. 
Also, the safe doses for subsequent clinical studies and the route of 
administration should be studied (Celis et al. 2015; Salmikangas et al. 2010). 
The beneficial effects of MSCs have been demonstrated in a wide range of 
pre-clinical development disease models and the results of clinical studies 
have led to the conclusion that MSC applications are safe and feasible 
(Ancans 2012). 
One of the central elements in the ATMP regulation is the GMP 
requirements that are mandatory to ensure safety and reproducibility of the 
product. For the culture of MSCs for clinical studies, a formal approval from 
competent regulators is needed. This approval is only granted if the cells are 
cultured according to GMP. Thus, the cells need to be cultured under the 
highest standards of sterility, quality control, and documentation, in 
accordance with a standard operating procedure. The basic GMP 
requirements mean that all manufacturing processes are clearly defined and 
systematically reviewed. The critical steps (including processes, equipment, 
and facilities) of the manufacture need to be validated, the personnel must be 
appropriately qualified and trained, traceability of all materials must be 
arranged and instructions must be clearly written, with records of all the 
steps during manufacture being mandatory (on-time recording). Also all 
significant deviations need to be fully recorded and investigated, and 
preventative actions must be implemented. To assure the quality of the cell 
product, quality controls (process and final product) must include 
bacteriological, phenotypic, viability, safety, and efficacy tests. The release 
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criteria are product dependent and must be defined separately for each 
therapeutic product. 
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2 AIMS OF THE STUDY 
The aims of this study were: 
1. To establish an efficient culture method to obtain MSCs from CB. 
2. To establish a robust culture method to culture BM-MSCs for 
clinical use. 
3. To gain knowledge about the impact of different culture conditions 
on MSC characteristics and functionality. 
4. To gain basic knowledge about the immunomodulatory 
mechanisms of MSCs. 
Materials and methods 
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3 MATERIALS AND METHODS 
3.1 ETHICS 
The study was approved by the ethical review board of the Finnish Red Cross 
Blood Service and the Ethical Committee of the Hospital District of Helsinki 
and Uusimaa. Human CB and BM were collected from voluntary healthy 
donors after written informed consent. Only CB-units unsuitable for clinical 
banking due to a too low blood volume or cell amount were used in the 
studies. 
3.2 METHODS 
Materials and methods used in the studies are described in detail in the 
original publications (I-IV) and are listed in Table 6.  
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 Materials and Methods used in publications I-IV in the thesis. Table 6.
Method used in study 
Cell  and EV isolation methods  
- density-gradient centrifugation  
? isolation of MCs from CB I, II 
? isolation of MCs from BM III 
? peripheral blood MC (PBMC) isolation II, III, IV 
- magnetic bead cell separation  
? isolation of CD3+ T cells IV 
- ultracentrifugation  
? EV collection from cell culture supernatant IV 
Preparation of platelet-derived cell culture supplements III 
Cell culture  
- culture of CB-MSCs I, II, IV 
- culture of BM-MSCs III, IV 
- MSC differentiation assays II, III 
? bone, adipose and cartilage  
Cell functionality tests  
- T cell suppression assay  
? co-culture of PBMCs and MSCs II, III 
? co-culture of T cells and MSCs IV 
- angiogenesis assay II 
? tube formation assay of endothelial cells  
Fluorescence based characterization of cells  
- Flow cytometry  
? immunophenotype of MSCs II, III, IV 
? immunophenotype of T cells IV 
- Immunofluorescence microscopy IV 
? expression of CD73 and CD39 in MSCs  
Karyotyping III 
HOX expression II 
- Reverse transcription polymerase chain reaction (RT-
PCR) 
 
VEGF expression II 
- Quantitative real-time polymerase chain reaction (qRT-
PCR) 
 
- Enzyme-linked immunosorbent assay (ELISA)  
EV analysis IV 
- Nanoparticle tracking analysis (NTA)  
Nucleotide measurements IV 
- High-performance liquid chromatography (HPLC)  
Materials and methods 
42 
 DIFFERENT CULTURE MEDIA 3.2.1
Different culture media used in the CB-MSC studies are listed in table 7 and 
in table 8 for the BM-MSC studies. 
 The compositions of culture media used in the CB-MSC studies. StdM was used Table 7.
 as standard growth medium of CB-MSCs (publications I, II, IV) and in the 
 functional studies of CB-MSCs (publication II). M1 medium was used in the long 
 term culture studies of CB-MSCs and in the functional studies of CB-MSCs 
 (publication II). M2 medium was used in the functional studies of CB-MSCs 
 (publication II). M3 medium was used as an assay medium in the functional 
 studies of CB-MSCs (publication II). 
medium component StdM M1 M2 M3 
alpha-MEM GlutamaxTM x x x x 
penicillin 
streptomycin 
100U/ml 
100μg/ml 
100U/ml 
100μg/ml 
100U/ml 
100μg/ml 
100U/ml 
100μg/ml 
FBS 10% 5 % 5 % 5 % 
DX 50 nM - - 50 nM 
EGF 10 ng/ml - 10 ng/ml 10 ng/ml 
PDGF-BB 10 ng/ml 10 ng/ml 10 ng/ml - 
StdM = Standard growth medium, M1= Medium 1 and M2 = Medium 2, M3 = Medium 3, 
X=included in medium 
 
 
 
 
 
 The composition of growth media used for the BM-MSC studies (publication III). Table 8.
medium component FBS-medium PL1-medium 
PL2-
medium 
DMEM-LG x x x 
penicillin 
streptomycin 
100U/ml 
100μg/ml 
100U/ml 
100μg/ml 
100U/ml 
100μg/ml 
FBS 10% - - 
Heparin - 40 IU/ml 40 IU/ml 
PL1* - 10% - 
PL2* - - 0.5% 
AB-plasma - - 2.5% 
FBS = fetal bovine serum, PL1 = platelet lysate 1 supplement, PL2 = platelet lysate 2 supplement 
*Different platelet concentration in lysate 
X=included in medium 
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4 RESULTS 
4.1 AN EFFICIENT METHOD TO CULTURE MSCs FROM 
CB 
 THE SUCCESS RATE OF OBTAINING MSCs FROM CB 4.1.1
CB has proven to be a challenging material to obtain MSCs from. In our 
laboratory, in the early stages of the development of the method to culture 
MSCs from CB, several trials were made using either low serum (2% FBS) 
containing medium with several growth factors or high serum (15% FBS) 
containing medium with fewer growth factors (Laitinen and Laine 2007). 
These methods were carried out in normal atmospheric O2 concentration. As 
the success rate of obtaining MSCs with these methods was low (data not 
shown), the method was further improved. The standard growth medium 
(StdM, Table 7) was developed based on information on MSC supporting 
factors in literature.  
With the improved method, MSCs were successfully generated from 14 
out of 16 CB-units, which corresponds to a success rate of 87.5%, when cells 
from CB were cultured in StdM on FN-coated plates in 3 % O2 concentration. 
The mean volume of the CB units was 58.6 ± 19.2 ml. MSC could even be 
obtained from small CB-units of 42 ml in volume. The mean MC count after 
density gradient centrifugation was 382.6 ± 124.2. There was no correlation 
between the CB unit volume or MC number and MSC amount in passage 1 
(p1) (R2 = 0.0374 and R2 = 0.0023, respectively). The storage time of CB-
units before processing was over 19 h (mean 23.97 ± 5.88 h, publication II 
Table 2). The success rate of obtaining MSCs from almost 90% of CB-units 
that were stored for over 19 hours (and included even small units) is much 
higher than the success rate reported earlier in literature for human CB-
MSCs. 
 THE IMPACT OF CULTURE CONDITIONS ON THE 4.1.2
PROLIFERATION OF CB-MSCs 
Several growth factors are thought to be beneficial for MSC growth. In our 
laboratory, the importance of different components in the StdM on cell 
proliferation was tested by excluding growth factors from medium. These 
tests indicated PDGF-BB to be a critical factor for efficient CB-MSC 
proliferation since the proliferation was radically diminished without PDGF-
BB (data not shown) and therefore it was included in all growth media used 
for CB-MSCs in the studies of this thesis. Also O2 concentration in cell culture 
has been demonstrated to influence cell proliferation. 
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In this thesis, the impact of culture conditions on the proliferation of CB-
MSCs was studied. To see the effects of different culture media on long term 
proliferation of CB-MSCs, the cells were cultured in parallel in two different 
media, StdM and M1 (Table 7), from passage 2 on. For the purpose of 
investigating the impact of O2 on the long term cultures of CB-MSCs, the cells 
were also cultured in two different O2 concentrations (3% and 20%).  
The results showed that CB-MSCs from the studied cell batches were 
capable of proliferating for up to 17 passages before senescence. Although the 
capacity of CB-MSCs to proliferate differed between  CB-MSC batches, MSCs 
cultured in StdM, which contained more growth factors compared to M1 
medium, proliferated better and reached higher PD numbers in shorter time 
than CB-MSCs cultured in M1 medium, irrespective of the O2 concentration. 
The combination of an optimal culture medium and 3 % O2 concentration 
gave the best results in terms of the CB-MSC growth. CB-MSCs showed the 
greatest capacity to proliferate when cultured in StdM in 3% O2 
concentration. The supportive effect of 3% O2 concentration on cell 
proliferation was seen more clearly at late passages than at early passages 
(Table 9, Figure 3 and publication II Figure 3). 
 The proliferative capacity of the MSCs in different culture conditions in the long Table 9.
 term cultures of CB-MSCs. The numbers of cumulative PDs, the culture length 
 in days (d) and passage numbers (p) reached by CB-MSCs from two different 
 CB-units. (Modified from Laitinen et al 2016, publication II Figure 3). 
CB-unit 
name 
391P 454T(7) 
medium StdM M1 StdM M1 
 PD d  p PD d p PD d p PD d p 
3% O2 51 57  16 42 85 17 48 59 17 32 71 14 
20% O2 47  63 17 35 66 14 40 56 15 26 66 13 
StdM = Standard growth medium, M1= Medium 1 
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 Long term culture of CB-MSCs in two different media and in two different oxygen Figure 3
 concentrations. Cells from CB-units (A) 391P and (B) 454T(7) cultured from 
 passage 2 until senescence. The supportive effect of 3 % O2 on cell proliferation 
 was more obvious at late passages. (Modified from Laitinen et al 2016, publication 
 II Figure 3). 
4.2 DEVELOPMENT OF CULTURE METHOD FOR 
CLINICAL-GRADE BM-MSCs 
 DEVELOPMENT OF PL SUPPLEMENTS 4.2.1
Efficient xeno-free expansion methods to culture MSCs for clinical use are 
strongly encouraged by regulators. Human platelet-derived supplements 
have been widely studied to find substitutes for bovine derived FBS. In this 
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thesis, two different platelet-derived PLs, PL1 and PL2, were produced for 
use as supplements in BM-MSC culture media (Table 8). PL1 was produced 
by pooling several PRP units that had been frozen once before pooling. PL2 
was produced from platelet concentrates by efficiently lysing the platelets 
with five freeze-thaw cycles before pooling several of these units. The 
efficiency of these supplement-pools to support MSC growth were tested in a 
5-7 day BM-MSC proliferation assay.  
PL1 pools of different sizes (produced from different number of PRP 
units) were tested using 2–4 individual MSC batches as responder cells. The 
tested pools supported consistently the proliferation of BM-MSCs, with the 
cells reaching 3-6.2 PDs during the proliferation assay (publication III Table 
2). The pools produced from two PRP units were noted to be as efficient in 
supporting MSC proliferation as those produced from 13 units. For PL2, all 
units used for the pool were individually tested and shown to support MSC 
growth at least as well as FBS-containing medium.  
 THE IMPACT OF CULTURE CONDITIONS ON BM-MSC 4.2.2
PROLIFERATION 
Efficient GMP-compliant methods are necessary for the expansion of a 
sufficient number of BM-MSCs for clinical needs from a limited amount of 
BM. In this thesis, two different GMP-compliant culture media, PL1 and PL2, 
were compared against FBS-medium (Table 8) in regard to their ability to 
support the proliferation of BM-MSCs at early passages of the cells (up to 
passage 2). We also tested the capacity of these different media to support 
the long term proliferation of BM-MSCs. The impact of O2 concentration on 
the cell proliferation at early passages was also studied. 
The short term cultures (up to passage 2) indicated that the PL1-medium 
had better capacity to support the growth of BM-MSCs regardless of O2 
concentration compared to PL2-medium as the PD time was significantly 
shorter when BM-MSCs were cultured in PL1-medium (p=0.015). There was 
no statistical difference observed in the PD times between FBS- and PL1-
medium cultured cells. Also, there was no statistical difference in total cell 
yield or cumulative PDs between different culture conditions (p = 0.42 and 
0.99, respectively) (Figure 4). Though the difference was not statistically 
significant, there was a trend indicating that 3% O2 concentration might 
support a shorter PD time (Figure 4c). The most obvious difference in PD 
times was observed between cultures of PL1-medium in 3% O2 and PL2-
medium in 20% O2 (p=0.04), with the PD time at passage 2 being 1.7 ± 0.3 
and 4.2 ± 2.0 days, respectively. The long term culture of BM-MSCs in 
different media also indicated the effectiveness of PL1-medium as PL1-
medium cultured cells reached  higher PD numbers (46) before senescence 
than PL2- and FBS-media cultured cells  (27 and 38 PDs, respectively, 
publication III Figure 4). 
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 Results from BM-MSC cultures in three different media and in two different oxygen Figure 4
 concentrations. (a) Extrapolated cell yields from 20 ml of BM up to passage two. (b) 
 Cumulative PDs and (c) PD time at different passages from BM-MC up to passage 
 2. Data represented as mean ± SD. (From Laitinen et al. 2015, publication III 
 Figure1) 
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As the PL1-medium proved to be the most potent proliferation medium of 
the media tested, it was chosen for further studies. The further studies were 
conducted in 20% O2 concentration as the 3% O2 concentration did not 
significantly enhance cell proliferation. The effectiveness in obtaining 
clinically relevant numbers of BM-MSCs in PL1-medium within two cell 
passages was studied in detail. The aim was to reach clinically relevant cell 
numbers (109) starting from 20 ml of BM within two cell passages. This aim 
was reached with 73 % of the cultured BM batches within 21-35 days 
(publication III Figure 2). The main reason for not reaching this limit set for 
cell numbers was the initial quality of the BM sample (clots in BM sample). 
Thus with good quality BM samples, the success percentage was even higher. 
4.3 CHARACTERISTICS OF MSCs AND THE IMPACT OF 
CULTURE CONDITIONS 
 PHENOTYPE 4.3.1
MSCs from both BM and CB expressed the typical MSC markers, as shown by 
immunophenotyping with flow cytometry. The cells were positive for CD13, 
CD29, CD44, CD49e, CD73, CD90, CD105, and HLA-ABC, and they were 
negative for CD14, CD19, CD34, and CD45. Differences in expression of HLA-
DR and CD90 were seen when culturing the cells in different conditions. 
BM-MSCs cultured in PL1-medium were constantly positive for HLA-DR 
but the level of positivity varied between cell batches, with 7.5%-66.1% of the 
cells expressing this molecule on their surface. The expression of HLA-DR 
was also seen on PL2-medium cultured cells. On FBS-medium cultured cells, 
no HLA-DR positivity was detected (publication III Figure 6). 
With CB-MSCs, the flow cytometric analysis of the cells revealed the cell 
surface expression of CD90 to be lower on cells cultured in growth factor rich 
and DX-containing medium, StdM, compared to cells cultured in medium 
with less growth factors, M1. The expression of CD90 was sustained through 
the passages on the cell surface of the CB-MSCs cultured in M1 but it was 
clearly diminished on StdM cultured cells (publication II, Figure 4).  
 HOX FINGERPRINT 4.3.2
The HOX code has been introduced as a marker to distinguish CB-derived 
cell types, such as HOX-positive CB-MSC and HOX-negative USSC (Liedtke 
et al. 2010). In this thesis, to characterize the HOX fingerprint of CB-MSCs 
the expression of 39 HOX genes distributed among four clusters (ABCD) 
were tested by RT-PCR. The expression profile of 39 HOX genes showed 
varied distribution within the A-D HOX clusters in MSCs from different CB-
units, indicating heterogeneity in CB-MSC populations of different cell 
batches. There were two batches of CB-MSCs expressing the genes from all 
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four clusters, two CB-MSC batches expressing the genes from ACD clusters, 
and one cell batch expressing the genes from BCD clusters. In two CB-MSC 
batches, there was almost no expression of the HOX genes in any of the 
clusters (publication II, Figure 2A). The HOX fingerprint indicated that there 
is heterogeneity in MSC populations obtained from CB. 
Changes seen in the expression profile during passaging were minimal as 
only some minor differences of the expression profile within the same HOX 
gene group were detected (publication II, Figure 2B). 
 DIFFERENTIATION POTENTIAL 4.3.3
According to the minimal criteria set for MSCs, these cells should have tri-
lineage differentiation capacity, with the ability to differentiate into 
osteoblasts, adipocytes, and chondrocytes (Dominici et al. 2006). In this 
thesis, the differentiation capacity of CB- and BM-MSCs was tested. While 
BM-MSCs were found to have all these differentiation capacities, the 
differentiation capacity of CB-MSCs was heterogenic as not all batches 
showed true tri-lineage differentiation.   
Only two of the tested CB-MSC batches retained the tri-lineage 
differentiation capacity with the others showing the capacity to differentiate 
into only two of the three lineages (publication II Table3 and publication II 
Figure 1). 10 of the tested 12 CB-MSC batches were capable of differentiating 
into osteoblasts and 5 of 10 tested batches differentiated into chondrocytes. 
Adipogenic differentiation was tested with two different methods, the 
traditional and the enhanced method (with PPARγ ligand), with positive 
differentiation seen in 1 of 9 CB-MSC batches when tested with traditional 
method and in 11 of 13 when using the enhanced method. Chondrogenic 
differentiation was detected with 5 of the 10 tested CB-MSC batches 
(publication II Table3 and publication II Figure 1). 
BM-MSCs were showed to have the capacity to differentiate into all three 
lineages (publication III Figure 5). Osteogenic differentiation was conducted 
using two different osteogenic differentiation media: FBS-containing and 
PL1-containing differentiation media. When the differentiation was 
conducted in FBS-containing osteogenic differentiation medium, BM-MSCs 
cultured in PL1-supplemented growth medium did not show strong 
osteogenic differentiation potential as the accumulation of calcium deposits 
was modest. In contrast, conducting the differentiation of BM-MSCs in PL1-
supplemented differentiation medium resulted in notably stronger 
differentiation (publication III Figure 5c and 5d). 
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4.4 THE IMPACT OF CULTURE CONDITIONS ON MSC 
FUNCTIONALITY 
 THE CAPACITY OF MSCs TO SUPPORT ANGIOGENESIS 4.4.1
To study the angiogenic supporting capacity of CB-MSCs cultured in 
different media, their ability to produce angiogenic factor, VEGF, was 
investigated with qRT-PCR and ELISA tests and their capacity to support 
tube formation of endothelial cells was verified in an in vitro angiogenesis 
assay. 
CB-MSCs expressed VEGF on mRNA and on protein levels. The VEGF 
mRNA expression was up-regulated in cells primed for five days in M1 and 
M2 media, the media without DX (fold change difference values 3.7 and 4.3, 
respectively), as compared to StdM primed cells. A similar difference was 
detected on the protein level with CB-MSCs first primed in different media 
(StdM and M1) and then transferred into identical culture medium (M3) for 
21h. The capacity of the CB-MSCs to produce VEGF varied between tested 
CB-MSC batches but the production was higher with cells primed in M1 
medium (publication II Figure 5A and B). 
In the in vitro angiogenesis assay, the CM of CB-MSCs was able to 
support tubule formation of endothelial cells. To compare this capacity in 
CB-MSCs primed in different media, the cells were first cultured in either 
StdM or M1 media and then transferred into the same medium (M3) for 21h 
before the collection of CM. The CM produced by M1 primed cells showed 
significantly better capacity (p<0.001) to support tube formation than the 
CM of StdM primed cells (publication II, Figure 5C). 
 THE CAPACITY OF MSCs TO SUPPRESS T CELL 4.4.2
PROLIFERATION 
The capacity of both BM- and CB-MSCs to suppress T cell proliferation was 
tested with an in vitro co-culture assay of MSCs and peripheral blood MCs 
(PBMCs) in which T cells were activated with anti-CD3 antibody. Both BM- 
and CB-MSCs had the capacity to suppress T cell proliferation. 
The capacity of CB-MSCs to suppress T cell proliferation differed 
significantly depending on whether the cells were primed in media with or 
without DX supplementation (StdM vs. M1 and M2). The suppression 
capacity was significantly diminished if cells were primed in M1 and M2 
media, compared to StdM primed cells (p<0.01 and p<0.05, respectively, 
publication II Figure 6). 
With BM-MSCs, there was no statistically significant difference detected 
in the MSCs’ capacity to suppress T cell proliferation when they were 
cultured in different culture conditions (different media PL1, PL2 and FBS 
and different O2 concentrations, 3% and 20%, p=0.14) (publication III Figure 
7).  
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 Summary of the results from characterization and functionality studies of CB- Table 10.
 and BM-MSCs cultured in different media. 
character/ 
functionality 
general 
criteria* BM-MSCs CB-MSCs 
  FBS PL1 PL2 StdM M1 M2 
CD90 + (≥95%) + + + ↓ ↑ nd 
HLA-DR - (≤2%) - ↑ ↑ - - nd 
adipogenesis +  + + + ↓ nd nd 
osteogenesis +  + + + ↓ nd nd 
chondrogenesis +  + + + ↓ nd nd 
immunosuppression + + + + ↑ ↓ ↓ 
angiogenic support + nd nd nd ↓ ↑ ↑ 
 
FBS=FBS containing medium, PL1= PL1 containing medium, PL2=PL2 containing medium 
StdM = Standard growth medium, M1= Medium 1, M2=Medium 2 
* ISCT criteria for human BM-MSCs cultured in FBS-medium (Dominici et al. 2006).  
↑ = increased surface expression/ differentiation/functional capacity 
↓ = decreased surface expression/differentiation/functional capacity 
nd = no data 
 
4.5 ADENOSINE PRODUCTION, ONE OF THE 
IMMUNOSUPPRESSIVE MECHANISMS OF MSCs 
CD73 is one of the positive markers for MSCs included in the minimal 
criteria for MSCs (Dominici et al. 2006). As it is an ectonucleotidase that 
converts AMP into immunosuppressive Ado, its role as an 
immunosuppressive factor of MSCs was studied in this thesis. In the 
extracellular space, AMP is produced from ATP by another ectonucleotidase, 
CD39. Thus the expression of this molecule, along with CD73, was studied on 
MSCs and MSC-EVs, as well as on T cells, the targets of immunosuppressive 
action of MSCs. To connect the expression of CD73 to the 
immunosuppressive function of MSCs, the production of Ado was measured 
from MSC cultures and from the co-cultures of MSCs and T cells, and the 
impact of Ado on the proliferation of T cells was studied.  
 EXPRESSION OF CD73 AND CD39  4.5.1
The expression of CD73 and CD39 was studied by flow cytometric analysis 
and immunofluorescence microscopy. The results showed that CB- and BM-
MSCs expressed CD73 on their cell surface (publication IV Figure 1H). CD39 
expression could be detected on the surface of BM-MSCs, but not on CB-
MSCs.  In both cell types, intracellular expression of CD39 was detected and 
it co-localized with CD73 in filopodia and the bulge areas of cell membrane 
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(publication IV Figure 1). The positive labeling of CD73 was also seen on CB-
MSC-EVs (publication IV Figure 2B). 
The expression of CD73 and CD39 on T cells was studied by flow 
cytometry after in vitro proliferation assay of these cells with or without the 
presence of MSCs in the assay. The expression of CD73 decreased 
significantly on T cells upon stimulation with CD3 and CD28 antibodies 
(p<0.05 for CD4+ T cells and p<0.001 for CD8+ T cells). On CD4+ T cells, the 
expression level of CD73 was low even without the stimulation, with about 
10% of the cells being positive. The unstimulated CD8+ T cells expressed 
CD73 at a higher level, with about 72% of the cells being positive. The co-
culture of stimulated T cells with MSCs significantly increased the expression 
of CD73 on both CD4+ and CD8+ T cells, compared to culture of stimulated T 
cells alone (p<0.001 and p<0.01, respectively). In CD4+ T cells, the 
expression of CD73 increased to a higher level than with unstimulated cells 
(publication IV Figure 6A). 
The expression of CD39 increased significantly on both CD4+ and CD8+ T 
cells upon stimulation (p<0.05 and p<0.01, respectively). The co-culture 
with MSCs did not have an impact on CD39 expression of the stimulated T 
cells (publication IV Figure 6B). 
 THE PRODUCTION OF ADENOSINE 4.5.2
To study if the enzyme activity of CD73 molecule is seen on BM- and CB-
MSCs, the production of Ado was studied by nucleotide measurements with 
HPLC from CM of MSC cultures supplemented with AMP or ATP. MSCs were 
capable of efficiently producing Ado from AMP but not from ATP. This 
production from AMP was inhibited dose dependently with CD73 inhibitor. 
The nucleotide measurements from CD3 enriched T cell cultures indicated 
that T cells produced AMP from ATP but could not produce any significant 
amounts of Ado (publication IV Figure 3A). Similarly to MSCs, CB-MSC-EVs 
had the capacity to produce Ado from AMP but not to any great extent from 
ATP (publication IV Figure 3B), and this capacity was also blocked with 
CD73 inhibitor.  
When stimulated T cells were combined with MSCs in the culture, Ado 
could be produced from ATP (publication IV Figure 3C). The stimulation of 
MSCs with cytokines did not significantly impact their capacity to produce 
Ado from ATP (publication IV Figure 4). 
 THE EFFECT OF ADENOSINE IN AN IMMUNOSUPPRESSION 4.5.3
ASSAY 
To assess if Ado has the capacity to suppress T cell proliferation in an in vitro 
assay, pure Ado was added into the culture of stimulated T cells.  The results 
showed that the addition of Ado could dose dependently suppress T cell 
proliferation if the adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-
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nonyl)adenine (EHNA), was also present in the assay (publication IV Figure 
5A and B). A similar effect could not be detected without EHNA, indicating 
the presence of adenosine deaminase, which rapidly degrades Ado, in the 
assay.  
To study if Ado plays a role in a four day co-culture assay of CB-MSCs and 
stimulated T cells, ATP was added to the assay with EHNA. In this assay, 
IDO is the predominant mechanism used by MSCs to suppress T cell 
proliferation. The addition of ATP to the co-culture in the presence of EHNA 
resulted in enhanced suppression of T cell proliferation, as compared to the 
suppressive effect of co-cultures without these additions. The effect was seen 
more clearly with CD8+ cells and in assays where the original suppressive 
capacity of MSCs was not very high (publication IV Figure 5C and D). Thus, it 
is likely that Ado production is one mechanism used by MSCs to suppress T 
cell proliferation. 
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5 DISCUSSION 
5.1 THE ESTABLISMENT OF EFFICIENT AND ROBUST 
CULTURE CONDITIONS FOR CB- AND BM-MSCs 
MSCs are isolated and cultured from many different tissues (Caplan 1991; 
Erices et al. 2000; Friedenstein et al. 1976; Gronthos et al. 2000; in 't Anker 
et al. 2004; Wang et al. 2004; Zuk et al. 2002). As MSCs are only found in 
small numbers in the body they cannot just be collected and given directly to 
a patient. The in vitro culture of MSCs is an unavoidable step required to 
gain an adequate number of cells for research and clinical use. Thus, an 
efficient method to culture these cells is crucial when establishing the basis 
for clinical cell production. 
For years, BM has been the standard source of MSCs, which have 
traditionally been thought to be part of the same general population, 
regardless of the tissue source. Comparative studies have, however, indicated 
clear differences between cells from different tissues (Chang et al. 2006b; Jin 
et al. 2013; Kern et al. 2006; Wagner et al. 2005) and thus it has been 
suggested that different MSC sources may generate MSC products suited to 
specific clinical applications (Horwitz and Dominici 2008). 
In this thesis the aim was to investigate if there was a possibility to 
establish a method to increase the gain of MSCs from CB. The aim was also to 
establish a method to produce MSCs for clinical purposes. As BM is an easier 
material to produce MSCs and BM-MSCs have already been used in clinical 
studies, we compared two different GMP-compliant methods to produce 
clinically relevant numbers of BM-MSCs. The GMP-compliant medium 
efficient for BM-MSC culture was also tested for CB-MSC establishment, but 
it seemed not to be sufficient to obtain MSC from this source (data no 
shown). Thus, the GMP-compliant method to produce MSCs from CB still 
needs a lot of effort in further studies. 
CB-MSCs 
CB has been an attractive source due to its abundance and ease of access and 
the high proliferative capacity of the cells. But this source has turned out to 
be a difficult material to obtain MSCs from, with the success rate ranging 
from non-existing to 10%-63% (Bieback et al. 2004; Mareschi et al. 2001; 
Montesinos et al. 2009). Higher success rates have been gained only if the 
processing time has been kept to a minimum or units of a certain size have 
been used (Zhang et al. 2011). In this thesis, an efficient method to obtain 
MSCs from almost 90% of CB units is presented (publications I, II). This 
figure is considerably higher than the rates reported previously.  
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MSCs from CB seem to need more support for their in vitro growth than 
MSCs from BM. In our method for CB-MSCs, the supporting factors for these 
cells come in the form of growth factor-rich medium (StdM) containing EGF, 
PDGF, and DX in addition to FBS. The other important constituents 
contributing to the support of CB-MSC growth are FN-coated culture plates 
and an atmosphere with an O2 concentration close to the physiological O2 
concentration, which is on average 3% on the tissue level (Haque et al. 2013). 
Although we have established an efficient method for receiving MSCs 
from CB, plenty of further development is required before the method is 
GMP-and clinically-compliant. As using animal-derived components in cell 
culture always carries a risk of transmission of xenogeneic infectious agents 
and immunization(Cervenakova et al. 2011; Horwitz et al. 2002; Liu et al. 
2008), the regulators urge the use of alternative supplements 
(EMEA/CHMP/410869/2006 and EMA/410/01 rev.3). Thus, the first 
critical step is to replace FBS in the culture medium. As also the quality of 
biologically active additives, such as growth factors, needs to be tested and 
documented with respect to identity, purity, sterility, and biological activity 
of the components as well as for the absence of adventitious agents, the 
amount of work is tremendous if several components are included in the 
culture medium, as in StdM.  Also, the practicality and financial aspects need 
to be considered when establishing culture methods. 
BM-MSCs 
BM seems to be an easier source in terms of obtaining and culturing MSCs 
than CB as MSC cultures can be established from every BM sample of good 
quality (Kern et al. 2006). BM-MSCs have also been the first MSCs used for 
clinical purposes even though the production of the MSCs has been based on 
FBS-containing medium (Horwitz et al. 2002; Lazarus et al. 1995; Le Blanc 
et al. 2004). In our studies, we compared two different GMP-compliant 
culture media (PL1 and PL2) based on platelet lysate against FBS-containing 
culture medium in regard to their capacity to support the growth of BM-
MSCs (publication III). Based on these studies, we found the PL1-medium to 
be better suited to clinical production of MSCs as its production was more 
practical and it was superior in its MSC proliferation supporting ability. Thus 
we established our clinical BM-MSC manufacturing protocol based on this 
method. 
Crucial factors in MSC culture 
As a good cell yield is important when producing MSCs for clinical use, we 
analyzed the capacity of different cell culture conditions to support MSC 
proliferation. Another critical factor in in vitro cell culture, besides the 
composition of the medium, is the surrounding environment. Cells are 
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usually cultured in 5% CO2 concentration, which reflects the CO2 conditions 
in vivo (Csete 2005). The buffering capacity of the traditional culture media 
is optimized for use in this CO2 concentration. The O2 conditions are often 
ignored in tissue culture as the O2 concentration is more complicated to 
regulate. However, the concentration of O2 is important for virtually all cell 
processes (Csete 2005). In our studies, we produced evidence showing that 
low O2 (3%) enhances the capacity of the MSCs to proliferate but this effect is 
more evident at late cell passages than in the early stages of culture 
(publications II, III). The combined effect of optimized culture medium and 
low O2 gave the best results as the BM-MSCs cultured in PL1-supplemented 
medium in 3% O2 concentration showed the shortest PD (publication III) 
time. Correspondingly, the CB-MSCs cultured in medium with the richest 
growth factor content (StdM) in 3% O2 concentration reached the highest 
cumulative PD numbers in the shortest time (publication II). Although a 
positive influence of low O2 concentration was seen in our studies, the impact 
of low O2 was only minimal at the early passages of cell culture (publication 
III). For safety reasons, the method of choice for MSCs to be used for clinical 
purposes is to culture the cells in vitro for as short a time as possible 
(Wuchter et al. 2015) and therefore the O2 concentration is not a critical 
factor when improving the cell yield in the early passages. In our studies, 
more impressive differences in the proliferative capacity of MSCs were seen 
between cells cultured in different media, with StdM being better than M1 for 
CB-MSCs and the PL1-medium being better compared to PL2 for BM-MSCs 
(publications II, III). 
As expected, we found the growth factor-rich medium, StdM, to be more 
efficient in supporting the growth of CB-MSCs (publication II). The culture 
supplements EGF, PDGF, and DX have also been used by others to support 
cell growth (Reyes et al. 2001). The combination of PDGF and FN-coating of 
plastic-ware has been demonstrated to have a positive influence on the MSC 
proliferation (Veevers-Lowe et al. 2011). Veevers-Lowe et al. have shown that 
MSC adhesion to FN induces the α5β1-integrin (CD49e and CD29, both 
strongly expressed on MSCs) dependent phosphorylation of PDGF-receptor β 
(PDGFR-β). The adhesion to FN also strongly potentiates the PDGF-BB-
induced phosphorylation of the receptor. This phosphorylation of PDGFR-β 
leads to downstream signal transduction, finally resulting in the stimulation 
of cell growth and motility as well as cell proliferation (Veevers-Lowe et al. 
2011). EGF has been shown to maintain the colony forming capacity of MSCs, 
thus EGF helps to preserve early progenitors in MSC populations (Tamama 
et al. 2010). It has been indicated that DX  increases proliferation, and the 
positive effect of DX at the beginning of CB-MSC culture may be a result of 
its inhibitory effect on monocytes adherence on culture plates (Roberts et al. 
1998), thus allowing more space for MSCs to proliferate. 
It could be speculated that the excess of growth factors may negatively 
affect MSC growth, for example shortening the life span of MSCs. However, 
in our studies we did not see any negative effect of growth factor rich 
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medium on CB-MSC growth, as MSCs in StdM reached higher population 
doubling numbers than MSCs in M1 medium. We also did not notice any 
abnormalities in the karyotype of CB-MSCs that were tested in early passages 
(passage 4) and at late passages (passage 14-16, data not shown). 
Nevertheless, to resolve if growth factor rich medium affects the stability of 
MSCs in other respect still needs further studies. 
The two different PL supplements, PL1 and PL2, used in BM-MSC culture 
media, differed in their composition (Table 11) as PL2 was produced from 
PRP units and PL2 from platelet concentrates. The PL2 supplement was 
more concentrated and thus only a PL content of 0.5% was used in the final 
PL2-medium, compared to 10% PL1 supplement in PL1-medium, to have 
comparable numbers of lysed platelets between these supplements in final 
media. The PL1-supplement contained more AB-plasma, thus it was not 
necessary to add plasma to the PL1-medium. The plasma concentration of 
PL2-medium was lower although some AB-plasma was added to it. Another 
difference between these supplements was the number of freeze-thaw cycles 
applied, with PL2 being efficiently lysed with five cycles. Although the initial 
platelet counts of the supplements used to prepare the final media were 
comparable, the PL1 supplemented medium had better capacity to support 
MSC growth. It has been demonstrated that the freezing and thawing of PL 
has an effect on the growth factor composition of the supplement (Mojica-
Henshaw et al. 2013) and consequently the high number of freeze–thaw 
cycles during the manufacture of PL2 may have inactivated some critical 
components in this supplement. Also the plasma content of medium has 
proved to be an important factor for cell proliferation (Horn et al. 2010). 
 Characteristics of the PL1 and PL2 supplements and their use in BM-MSC Table 11.
 growth media (Modified from Laitinen et al. 2015, publication III Table 1) 
  
COMPOSITION OF 
PLATELET 
 UNITS/BAGS 
PLATELET 
 LYSATE MSC GROWTH MEDIA 
Supp- 
lement Description 
Platelets  
x10^9* 
Lysate 
 additive 
Lysed 
platelets 
x10^9/ml* 
Freeze- 
thaw 
cycles 
Pool size    
(nr of  
platelet 
units) 
Concentration 
of platelet 
lysate (%) 
Lysed 
platelets 
x10^8/ml* 
Concentration 
of plasma (%) 
PL1 
Platelets in 
plasma, 4 
donors BC 
300 AB plasma 0.1 2 2-13 10 1.0 10 
PL2 
Platelets in 
30% 
SSP/70% 
plasma, 4 
donors BC 
300 
Octaplas 
AB (pooled 
virus-
inactivated 
fresh 
frozen 
plasma) 
15 5 15 
0.5 
 (+ 2.5 % 
Octaplas AB) 
0.8 3 
*mean numbers 
BC= buffy coat 
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5.2 IMPACT OF CULTURE CONDITONS ON MSC 
CHARACTERISTICS AND FUNCTIONALITY 
Although a good cell yield is the basis for producing cells for clinical use, it 
cannot override the quality and the properties of the cells. Culture conditions 
have been suggested to influence the properties of MSCs (Bieback et al. 2010; 
Roobrouck et al. 2011b; Wagner et al. 2005) and thus the impact of different 
culture conditions on cell properties should always be carefully examined. 
The possible alterations in the properties of MSCs can be observed by 
studying the phenotype or expression of certain molecules of the cells. Also, 
conducting several functional tests may help to elucidate the influence of 
culture conditions on cell properties. Any possible alterations in cellular 
phenotype are easily observed but the link between the expression of a 
particular molecule and a relevant function of MSCs is not usually known. 
HLA-DR is one of the molecules that should not be expressed on the MSC 
cell surface according to the original minimal criteria to define MSCs 
(Dominici et al. 2006). This molecule is an example of how culture 
conditions may affect the phenotype. Certain inducing factors, such as IFN-γ 
and bFGF, have been shown to induce the expression of HLA-DR on MSCs 
(Le Blanc et al. 2003a; Romieu-Mourez et al. 2007; Sotiropoulou et al. 
2006). Lately, the classification of this molecule as a negative marker for 
MSCs has been criticized as its expression is dependent on the culture 
conditions (Tarte et al. 2010). In our studies, HLA-DR expression levels 
differed depending on whether the BM-MSCs were cultured in PL1, PL2, or 
FBS-containing media (publication III). Although HLA-DR was expressed at 
different levels on these cells, the capacity of the cells to suppress T cell 
proliferation did not change in our in vitro assay. Others have also indicated 
that the expression of HLA-DR is not connected with the capacity of MSCs to 
inhibit T cell proliferation (Sotiropoulou et al. 2006; Tarte et al. 2010). 
One MSC marker, for which variable expression was observed in our CB-
MSC culture experiments when culturing the cells in different media, was 
CD90 (publication II). Its expression was decreased when culturing the cells 
in StdM, the growth factor-rich medium. Others have not reported the effects 
of growth factors on the expression of CD90 but the impact on other 
molecules, such as CD105 and CD146, has been reported (Gharibi and 
Hughes 2012). The connection between this marker and the functionality of 
MSCs is not been clearly demonstrated. A decrease in CD90 expression has 
been linked to the differentiation processes and diminished 
immunosuppressive capacities of MSCs (Sibov et al. 2012). In our 
experiments, functional consequences were not studied. There are also 
arguments against CD90 as a “specific” MSC marker as several groups have 
noticed only low-level expression of CD90 on CB-MSCs (Goodwin et al. 
2001; Lee et al. 2004b; Montesinos et al. 2009; Nagano et al. 2010). Until a 
clear association between a particular phenotypic character and the 
functionality of MSCs is demonstrated, it cannot be concluded that a specific 
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phenotype leads to certain functional capacities of the cells and thus the 
functionality of MSCs should be somehow tested when altering culture 
conditions. 
In our studies, the MSC batches obtained differed in their HOX gene 
expression pattern, which did not considerably change during passaging. 
This indicates heterogeneity in the cell populations obtained from individual 
CB units. Therefore, although the characteristics of MSCs can be influenced 
by culture conditions, there may be limitations as the initial culture 
conditions may eliminate some subtypes of cells from the MSC population. 
This was also proposed by Buchheiser et al. when they noted that culture 
conditions during cell generation may be more critical than temporary 
changes in O2 concentrations and different cell populations may be generated 
at different frequencies depending on the O2 concentration (Buchheiser et al. 
2012). 
It has been suggested that cell culture conditions could be modified to 
receive MSCs optimized for a specific clinical indication (Horwitz and 
Dominici 2008). In our studies, we show that culture conditions have an 
effect on the functionality of MSCs in vitro. With CB-MSCs, we demonstrated 
that although StdM, the growth factor-rich medium, had the greater ability to 
support the growth of MSCs, its ability to promote the angiogenic supporting 
capacity of MSCs was diminished, as MSCs cultured in this medium 
expressed VEGF mRNA at a lower level than cells cultured in medium 
containing less growth factors and without DX, M1, and M2 media. MSCs 
induced in different media and then transferred into similar conditions still 
showed divergent potential to produce VEGF and to support angiogenesis in 
an in vitro tubule formation assay (publication II). This demonstrates the 
inductive impact of culture conditions to influence the angiogenic capacity of 
MSCs. On the other hand, our experiments showed that MSCs cultured in the 
presence of DX had a greater capacity to suppress T cell proliferation in an in 
vitro T cell proliferation assay (publication II). Thus when optimizing the 
culture conditions, for instance, to achieve higher cell yields, one should bear 
in mind that the changes in culture conditions may have an effect on the 
functionality of the cells, which is not always seen simply as alterations in the 
phenotype of the cells. 
Another indication of culture conditions having an impact on the 
functionality of MSCs was seen in our experiment aimed at differentiating 
BM-MSCs into osteoblasts (publication III). When MSCs were initially 
cultured in PL1-containing medium their capacity to differentiate into bone 
forming osteoblasts was diminished if the differentiation was performed in 
traditional FBS-containing differentiation medium. When the differentiation 
was performed in PL1-containing medium the differentiation was much more 
pronounced. The adipogenic differentiation of the CB-MSCs also suggested 
that by altering the adipogenic differentiation medium, the CB-MSCs could 
be differentiated into adipocytes with increased frequency (publication II). 
The adipogenic differentiation of CB-MSCs has been demonstrated to be 
Discussion 
60 
weak (Bieback et al. 2004; Chang et al. 2006b; Manca et al. 2008; Yoshioka 
et al. 2015; Zhang et al. 2011). In our studies, the adipogenic differentiation 
was also shown to be very weak if the traditional differentiation medium was 
used. When the differentiation medium was optimized for CB-MSCs by using 
the PPARγ ligand, ciglitazone, the adipogenic differentiation was enhanced. 
5.3 ADENOSINE PRODUCTION AS AN 
IMMUNOSUPPRESSIVE MECHANISM OF MSCs 
MSCs have demonstrated to have many mechanisms to suppress immune 
reactions (Castro-Manrreza and Montesinos 2015). In this thesis, a relatively 
unknown immunosuppressive mechanism of MSCs via adenosinergic 
signalling is presented. 
We became interested in the CD73 molecule, an ectonucleotidase that 
converts AMP into a highly immunosuppressive purine nucleoside Ado, as 
the anti-CD73 antibody was one of the few antibodies produced in our 
experiments of whole cell immunizations of the mice (unpublished data in 
collaboration with Medix Biochemica). This CD73 molecule is constantly 
expressed on MSCs at high intensity. The immunosuppressive effects of 
CD73 have been demonstrated with Tregs, tumor cells, and recently with 
MSCs (Amarnath et al. 2015; Chen et al. 2013; Chen et al. 2016; Deaglio et al. 
2007; Ghiringhelli et al. 2012; Sattler et al. 2011). In our studies, we explored 
the capacity of MSCs to suppress T cell proliferation in an in vitro assay and 
our aim was to demonstrate the role of Ado in the MSC mediated T cell 
suppression (publication IV). 
The expression of CD73 was noted to differ between individual cell 
batches, but we did not notice any effect of the different culture conditions on 
the capacity of MSCs to express CD73. Interestingly the co-expression of 
CD73 and CD39 was observed in filopodia and the bulge areas of cell 
membrane, indicating the possibility that MSCs may have the capacity to 
transfer CD39 to their cell surface under certain stimuli, as demonstrated by 
others in a co-culture assay of MSCs and T cells (Saldanha-Araujo et al. 
2011). 
Using HPLC analysis, we saw that BM- and CB-MSCs and CB-MSC-EVs 
could efficiently produce Ado only from AMP. From ATP this was possible 
only if stimulated T cells were present together with MSCs in the assay, 
indicating that MSCs act synergistically with immune cells to produce 
immunosuppressive Ado in conditions containing ATP. As the Ado 
production was inhibited by CD73 inhibitor we could conclude that CD73 has 
a critical role in the production of Ado by MSCs. Though we saw the impact 
of CD73 inhibitor in the short time co-culture assays with HPLC analysis, we 
could not demonstrate its impact in our four day in vitro co-culture assay. 
The immuosuppressive impact of MSCs in the in vitro T cell suppression 
assay comes mainly from the effects of MSC-produced IDO as its inhibition 
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restores the proliferative capacity of T cells. This has also been demonstrated 
by others (Francois et al. 2012; Jones et al. 2007; Menard et al. 2013). 
Although the suppressive capacity of MSCs in the assay was mainly due to 
the action of IDO we could, however, see improvement in the suppressive 
impact of MSCs when the cultures were supplemented with ATP and 
adenosine deaminase inhibitor, EHNA, to stabilize the produced Ado. Even 
though the promoting effect of the adenosinergic pathway on the suppression 
of T cells was not outstanding in this assay, it indicated the Ado route as one 
of the mechanisms used by MSCs to suppress T cell proliferation. 
As in vitro assays are artificial with several additives that need to be 
added to co-cultures the conditions  never truly resemble the situation in 
vivo. Therefore it is difficult to demonstrate the immunosuppressive 
mechanisms of MSCs in a co-culture assay and to predict their true in vivo 
capacities. The suppressive effect of Ado has been demonstrated with an in 
vivo mouse GVHD-model and autoimmune uveitis model, as blocking Ado-
receptor with a receptor antagonist or blocking CD73 with CD73 inhibitor 
abrogated the ability of MSCs to suppress the inflammatory effects of T cells 
(Amarnath et al. 2015; Chen et al. 2016). Thus, adenosinergic pathway seems 
to be one relevant mechanism of MSCs to suppress immune reactions. 
In our studies, we also explored the expression of CD73 and CD39 on T 
cells in the in vitro T cell suppression assay. The capacity of MSCs to increase 
the expression of CD73 on stimulated T cells was significant. Similar impacts 
by MSCs on the CD73 expression on T cells have been demonstrated by 
others (Chen et al. 2016; Saldanha-Araujo et al. 2011). This indicates the role 
of MSCs to prime T cells to express CD39 and CD73, which both are needed 
for Ado production.  TGF-β has been introduced to act as an agent by which 
MSCs up-regulate the expression of CD73 on T cells (Chen et al. 2016). In our 
studies, we showed that also MSC-EVs are CD73 positive and thus it is 
intriguing to hypothesize that the CD73 positivity of T cells might be 
mediated by CD73 positive EVs. Whether EVs mediate the expression of 
CD73 on T cells or not, they still offer an active enzyme to enable the 
production of Ado via CD39 and CD73 molecules.  
 As natural Tregs are described as being positive for CD39 but negative for 
CD73, they would need assistance from neighboring CD73 positive cells or 
EVs to produce Ado. In vitro induced Tregs, on the other hand, are described 
as being positive for CD73, and therefore capable of producing Ado on their 
own (Whiteside et al. 2011). Our results indicated that the expression of 
CD73 increased on T cells in the presence of MSCs, but we did not specifically 
determine whether the number of Tregs had increased. CD8+ T cells 
expressed higher levels of both CD39 and CD73, thus pointing to the 
adenosinergic pathway being important also for other cell populations and 
not just for CD4+CD25+ Tregs. In any case, as our results showed, the 
overall capacity of stimulated T cell populations to produce Ado from ATP 
increases in the presence of MSCs as both adenosinergic pathway enzymes 
are present. This adenosinergic pathway might be a relevant mechanism for 
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MSCs to suppress immune cell reactions especially in tissue damage, 
where ATP is abundantly available and since MSCs have the capacity to home 
into areas of injury and inflammation.  
5.4 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
In this thesis, it was demonstrated that MSCs can be efficiently cultured from 
CB though this material is not as reliable as a source of MSCs as BM. 
Succeeding in obtaining MSCs from CB requires more from the culture 
conditions than to obtaining MSCs from BM. In this thesis, it was shown that 
many different growth factors, along with low oxygen concentration, were 
needed to efficiently obtain MSCs from CB. And as each additive in the 
culture medium should be of GMP-grade, the development of a GMP-
compliant CB-MSC production method still needs a considerable amount of 
effort. For BM-MSCs, one robust GMP-compliant culture method is 
presented in this thesis. 
The culture conditions of MSCs have impact on both the proliferative 
capacity of MSCs and the functional capacities of these cells. In this thesis, 
the impact of different culture media on the functional capacity of CB-MSCs 
to support angiogenesis and their capacity to suppress T cell proliferation 
was demonstrated. Similarly, the culture conditions certainly impact the 
functionality of MSCs from other sources.  
Many mechanisms for MSCs to produce their therapeutic effects have 
been presented. In this thesis, the Ado producing capacity of MSCs is 
demonstrated to be a novel mechanisms used by these cells to suppress T cell 
proliferation. As MSCs are capable of producing Ado from ATP in 
cooperation with T cells and as the level of ATP is usually high in situations 
such as tissue damage, this mechanism may be a crucial factor influencing 
the therapeutic effects of these cells in tissue damage indications. Extensive 
research is still required to elucidate, how the Ado producing mechanism, as 
well as other functional mechanisms of MSCs, operate in vitro and whether a 
particular mechanism is more important in a certain indication. If the 
importance of these mechanisms could be linked to the therapeutic outcomes 
of different MSC treatments, it might be possible to tailor specific MSCs for 
each indication, possibly by merely optimizing the culture conditions for the 
MSCs. Also, in vitro functional tests to determine the true in vivo potential of 
MSCs must be developed to ensure that the cells given to a patient are 
functional for that particular purpose.  
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